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METHODS AND COMPOSITIONS FOR
STIMULATING T-LYMPHOCYTES
The United States government ownsrights to the present
invention pursuant to Grants CA 57293 and CA 16672 from
the National Cancer Institute.
BACKGROUND OF THE INVENTION
A. Field of the Invention
The present invention relates generally to the field of
molecular biology, and particularly to the area of natural and
synthetic peptides. Moreparticularly, the invention discloses
HER-2/neu peptide, DNA segment, antibody compositions.
Various methods for making and using these compositions
are disclosed, such as, for example, the use of peptides and
antibodies in various pharmacological and immunological
applications, including the stimulation of cytotoxic
T-lymphocytes and cancer therapies.
B. Description of the Related Art
1. HER-2/neu Proto-Oncogene
The HER-2/neu proto-oncogene (HER-2) encodes a
transmembrane protein whose expression is enhanced in a
number of breast and ovarian tumors and correlates with
tumor aggressiveness. Because of its expression on normal
epithelial cells, HER-2 can be defined as a tumor-associated
antigen (Ag) and may be of interest as a target of a
therapeutic anti-tumor T-cell response. A CD3*CD8*CD4—
line isolated from cell cultures has been shown to lyse
HLA-A2*, HER-s* ovarian tumors but not natural killer
(NK) target K562 cells, and showed significantly higher
lysis of HER-2”8” than of HER-2”°” ovarian tumors. Some
inhibition of lysis was inhibited by HER-2 peptide-pulsed
HLA-A2* targets, suggesting that some epitopes may be
present on tumorcells associated with HLA-A2.
2. Tumor-Reactive T-Cells
Tumor reactive T-cells have been reported to mediate
therapeutic responses against human cancers (Rosenberg et
al., 1988). In certain instances, in human immunotherapy
trials with tumor infiltrating lymphocytes (TIL) or tumor
vaccines, these responses correlated either with in vitro
cytotoxicity levels against autologous tumors (Aebersold et
al., 1991) or with expression of certain HLA-A,B,C gene
products (Marincolaet al., 1992). Recent studies (Ioannides
et al., 1992) have proposed that in addition to virally
encoded and mutated oncogenes, overexpressed self-
proteins may elicit some degree of tumor-reactive cytotoxic
T-lymphocytes (CTLs) in patients with various malignancies
(Ioannideset al., 1992; Ioannideset al., 1993; Brichardetal.,
1993; Jerome etal., 1991). Autologous tumorreactive CTLs
can be generated from lymphocytes infiltrating ovarian
malignantascites (Ioannideset al., 1991), and overexpressed
proteins such as HER-2 maybetargets for CTL recognition
(Joannides et al., 1992).
Information on epitopes of self-proteins recognized in the
context of MHC Class I molecules remain limited, despite a
few attempts to identify epitopes capable of in vitro priming
and Ag-specific expansion of human CTLs. For example,
peptide epitopes have been proposed which are likely can-
didates for binding on particular MHCClass I Ag (Falk et
al., 1991), and somestudies have attempted to define peptide
epitopes which bind MHCClassI antigens.
Short synthetic peptides have been used either as target
antigens for epitope mapping or for induction of in vitro
primary and secondary CTL responsesto viral and parasitic
Ags (Bednarek et al., 1991; Gammonet al., 1992; Schmidt
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et al., 1992; Kos and Mullbacher, 1992; Hill et al., 1992).
Unfortunately, these studies failed to show the ability of
proto-oncogene peptide analogs to stimulate in vitro human
CTLs to lyse tumors endogenously expressing these anti-
gens.
3. Synthetic Peptides and T-Cell Epitope Mapping
Synthetic peptides have been shownto be a useful tool for
T-cell epitope mapping. However in vivo and in vitro
priming of specific CTLs has encountered difficulties
(Alexanderet al., 1991; Schild et al., 1991; Carboneet al.,
1988).It is generally considered that in vitro CTL priming
cannot necessarily be achieved with peptide alone, and in
fact, a high antigen density is thought to be required for
peptide priming (Alexanderet al., 1991). Even in the limited
instances when specific priming was achieved, APC or
stimulators were also required at high densities (Alexander
et al., 1991).
It is not clear when CTL induction by HER-2 peptides in
vitro was observed whetherthis reflects secondary activation
of CTL specific for, or cross-reacting with, the Ag of interest.
Whetherornotthis cross-reactivity can constitute the foun-
dation for developmentof an in vitro CTL response to tumor
remains to be determined.
Therefore, what is lacking in the prior art are universal
epitopes which are both immunodominant and CTL-
stimulating. Moreover, methods for the use of such CTL-
stimulating peptides would be most desirable in the treat-
ment of human cancers, particularly of breast and ovarian
etiology, and the development of cancer vaccines. Identify-
ing universal oncoprotein epitopes would permit not only an
increased understanding of tumor immunity and autoimmu-
nity in humans, but would also open the door to the design
of novel therapeutic strategies for proliferative cell disorders
such as human cancers, and particularly breast and ovarian
cancers.
SUMMARYOF THE INVENTION
The present invention seeks to overcome these and other
inherent deficiencies in the prior art by providing the iden-
tification of native and synthetic proteins or peptides derived
from the HER-2/neu proto-oncogene gene product, and
methods for their use in stimulating cytotoxic
T-lymphocytes. These selected “universal” immunodomi-
nant epitopic peptides, and their synthetically-optimized
derivatives are envisionedto be useful in the developmentof
tumor vaccines, and anti-cancer therapeutics. Pharmaceuti-
cal reagents resulting from these novel peptides and the
DNAsegments which encode them will also likely prove
useful as test reagents for the detection of HER-2/neu-
related polypeptides,facilitate the production of anti-peptide
antibodies specific to a range of HER-2/neu-related
polypeptides, and result in the stimulation and production of
cytotoxic T-lymphocytes specific for a variety of prolifera-
tive disorders including human cancer.
Synthetic peptide analogs can be used to define CTL
epitopes recognized by tumorreactive T-cells and to stimu-
late in vitro peptide-specific CTLs. Such CTLs can be
further evaluated for recognition of targets endogenously
expressing the particular antigen (Ag) and for Ag-specific
adoptive therapy.
Disclosed herein are compositions and methods for their
making and use in developmentof anti-cancer vaccines. The
generation in vitro of HLA-A2-restricted CTLs using
HER-2 synthetic peptide analogs as immunogens, and
peripheral blood mononuclear cells (PBMC) from healthy
volunteers as responder cells is also described. Lysis with
US 6,514,942 B1
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isolated CD8* T-cells from these CTL cultures was observed
using both HER-2 peptide-pulsed HLA-A2 from these CTL
cultures was observed using both HER-2 peptide-pulsed
HLA-A2 transfectants and HLA-A2* ovarian tumors
expressing high levels of HER-2 astargets.
Another aspect of the invention is the development and
maintenancein long-term culture a CD3*CD8*CD4-line by
restimulation with HER-2 peptide-pulsed autologous
PBMC. This line lysed HLA-A2*, HER-2”%” ovarian
tumors, but not HLA-A2*, HER-2”°” ovarian tumors. Tumor
lysis was inhibited by HER-2 peptide-pulsed HLA-A2*
transfectants, demonstrating that epitopes either similar or
cross-reactive with the ones recognized by CTLs on the
peptide used as immunogenin vitro are present on the tumor
cells. These CTL showed lowerlysis of targets pulsed with
unrelated peptides (analogs of Muc-1 core peptide where
HLA-A2 anchors were introduced).
A novel approach to developing tumorreactive CTLs is
disclosed which focuses on a target Ag expressed on the
tumorof interest and identifying CTLs induced in vivo or
developed in vitro that recognize this target Ag. In tumor
cells the level of expression of a particular protein may be
10°-10° fold higher than in normaltissue.
The inventors expect that a numberoftarget T-cell Ags on
human tumors may be derived from proteins that are
expressed at low levels in normalcells, and at significantly
higher concentration in tumor cells, such as overexpressed
proto-oncogene products (Ioannideset al., 1992). The ratio-
nale for this hypothesisis:first, peptides from self-proteins
which fulfill the criteria of MHC allele-specific motifs
should be capable of binding to the Ag binding pockets in
the MHCclass I heavy chain; and second, positive and
negative selection of T-cell repertoire may result in elimi-
nation or tolerization of high-affinity self-reactive CTLs
(Parmianai, 1993), although such peptide-MHC complexes
should have lower affinity for the TCR than a de novo
expressed epitope from a self-protein (as a consequence
either of mutations creating HLA-anchors or modifying the
core recognized by the TCR), their presence in high con-
centration may engage a large number of TCR.
The HER-2/neu proto-oncogene wasidentified becauseit
is overexpressed (in certain instances by several hundred
fold) in a numberof breast and ovarian tumors (Slamonet
al., 1989). Moreover, it was found that several CTL-TAL
lines isolated from ovarian malignant ascites could lyse
autologous ovarian tumors.
Surprisingly, the inventors also discovered that this lysis
could also be effectively inhibited by natural and synthetic
peptide analogs of HER-2. These results suggested that these
novel peptides acted as epitopes that were either derived
from an endogenously-processed HER-2 peptide, mimicked,
or cross-reacted with a peptide of related sequence derived
from another protein.
Novel synthetic peptide compositions have also been
developed which correspond to the HER-2:968-981 and
971-979 regions. The compositions disclosed herein, were
found to stimulate in vitro PBMCs from healthy HLA-A2*
human volunteers (Fisk et al., 1994), and CTLs (induced by
peptide stimulation) consequently lysed tumors overex-
pressing HER-2 (Fisk et al., 1994). These studies demon-
strated that these CTLs can effectively recognize the epitope
peptides of the present invention, and that these HER-2-
derived peptides can stimulate in vitro PBMCs to induce
peptide reactive CTLs.
This possibility may be particularly relevant for induction
of Ag and tumor-specific CTLs because peripheral T-cells
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that can recognize such peptides from non-mutated self
proteins are those that have either escaped elimination or
may have becometolerant to one or more of these antigenic
epitopes due to low affinity TCR-MHC interactions
(Joannides et al., 1992; Parmiani, 1993).
Other aspects of this invention include the identification
of candidate HER-2-derived T-cell epitopes based on the
presence of anchors for HLA-A2, the analysis of these
peptides to affect the conformation of HLA-A2 asan indi-
cation of peptide binding,andfinally, the demonstration that
these peptides can stimulate in vitro peptide reactive CTLs
from human HLA-A2* PBMC.
Methods are described herein for stimulation of CTLs
(and consequently, production of an immune response)
employing the novel compositions disclosed herein. In vitro
induction of cellular responsesto the peptides of the present
invention by PBMC from healthy HLA-A2* volunteers
demonstrated their ability to stimulate and/or restimulate
pre-existing T-cell responses to HER-2. The peptides
induced proliferative responses in one of four donors tested
and CTL responses (one of three peptides tested in two of
three donors), and may be used to induce tumor-reactive
T-cells in vitro and in vivo through either peptide-,
lipopeptide-, or cell-mediated methods. These peptides
therefore find utility in both generating an immuneresponse,
and serving as antigensin the preparation of peptide-specific
antibodies.
The peptides of this invention also may be used in
embodiments involving treatment, diagnosis, and identifi-
cation of proliferative cell disorders such as cancer, and
particularly cancers such as, inter alia, breast and ovarian
tumors. Methodsof identification of HER-2/neu-containing
cells, and also neu-related proto-oncogene and oncogene
products are also disclosed.
Cancer treatment methods, including vaccine develop-
ment are another aspect of the present invention.
Additionally, a variety of in vitro and in vivo assay protocols
are facilitated as a result of the novel compositions disclosed
herein. In addition to stimulating CTLs, and generating an
immune response in an animal, and particularly in a human,
the peptides may also be used as immunogens to generate
anti-peptide antibodies, which themselves have manyuses,
not least of which is the detection of oncogene-containing
cells (e.g., detection of HER-2/neu, related oncogenic
polypeptides, or peptide fragments thereof, in diagnostic
tests and kits based upon immunological binding assays).
Also, since the peptides of the invention bind to T-cells,
they may be employed in assays to identify T-cells, and
particularly CTLs, for example, to assess the immunological
capacity of a given individual or animal, or even to purify
CTLsthemselves. Such methods could utilize radioactively-
or enzymatically-labeled peptides or anti-peptide antibodies,
such as those described herein.
Therefore, one contemplated use for the described pep-
tides concerns their use in methods for detecting the pres-
ence of T-cells within a sample. These methods include
contacting a sample suspected of containing T-cells with a
peptide or composition in accordance with the present
invention under conditions effective to allow the peptide(s)
to form a complex with T-cells of the sample. One then
detects the presence of the complex by detecting the pres-
ence of the peptide(s) within the complex, e.g., by either
originally using radiolabeled peptides or by subsequently
employing anti-peptide antibodies and standard secondary
antibody detection techniques.
Preferred peptides of the present invention will likely be
from about 6 to about 20 amino acids, in length, with
US 6,514,942 B1
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peptides of from 7 to about 15 amino acids in length being
even more preferred. Most preferred are peptides having
lengths of from about 8 to about 10 aminoacids in length,
with nonameric and decameric peptides being most pre-
ferred. These peptides may include one or more D-amino
acids, or may even be entirely composed of D-aminoacids,
and may, of course, contain additional elements, as desired
for stability or even for targeting purposes.
The peptides, or multimers thereof, may be dispersed in
any one of the many pharmacologically-acceptable vehicles
known in the art and particularly exemplified herein. As
such, the peptides may be encapsulated within liposomes or
incorporated in a biocompatible coating designed for slow-
release. The preparation and use of appropriate therapeutic
formulations will be knownto those of skill in the art in light
of the present disclosure. The peptides may also be used as
part of a prophylactic regimen designed to prevent, or
protect against, possible cancer progression and/or metasta-
sis and may thus be formulated as a vaccine,particularly as
a method of stimulating anti-tumor CTLs.
The present invention also provides methods for identi-
fying HER-2/neu and related proto-oncogene products,
which methods comprise contacting the cells suspected of
containing such polypeptides with an immunologically
effective amount of a composition comprising one or more
specific anti-peptide antibodies disclosed herein. Peptides
that include the amino acid sequence of any of SEQ ID NO:1
through SEQ ID NO:29 and their derivatives will be pre-
ferred for use in generating such anti-CTL-stimulating pep-
tide antibodies.
The invention thus also provides compositions, including
peptides, peptide multimers, and pharmaceutical composi-
tions derived therefrom,that contain one or more peptides of
from 8 to about 20 amino acids in length that include within
their sequence the peptide sequence identified by the for-
mula: AA,-AA,-AA,-AA,-AA,-AA,-AA,-AA,; where
AA,is Leu, Met,Ile, or Val; AA, is any amino acid; AA,is
any amino acid; AA, is Ser, Glu, Thr, or Tyr; AA; is any
amino acid; AA, is any amino acid; AA, is any aminoacid;
and AA,is Val, Leu, Met, Ile, or Cys. These peptides are
submitted to be capable of stimulating CTLs and producing
an immuneresponse in vitro and in vivo.
Another aspect of the present invention concerns the use
of the amino acid sequences disclosed herein in the deter-
mination of molecular weights of low-molecular-weight
polypeptides. These peptides represent a significant
improvement over commercially-available protein standards
in this area owing to their small size, and the presence of
known nonapeptide motifs. Commercially-available stan-
dards typically have a range of 3,000 to 200,000 Da, and as
such,are not useful in the characterization of proteins having
molecular weights of about 300 to about 3,000 Da using
either conventional or gradient SDS-PAGE.
In a similar fashion, the peptides, and more particularly
peptide oligomers, of the present invention are readily
employed as standards in the identification of small
molecular-weight polypeptides using chromatographic sepa-
ration. In preferred embodiments, paper chromatographyis
utilized and proteins are subsequently visualized after reac-
tion with ninhydrin. More preferred is the use of thin-layer
chromatography in either one or two dimensions.
The use of the peptides and peptide motifs of the present
invention is also contemplated for the calibration and stan-
dardization of chromatographic columns used in the sepa-
ration of low-molecular-weight polypeptides. These
peptides, and multimers thereof, find important use in the
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calibration of low-molecular-weight-range columns. Such
molecularsieve (or gel filtration) chromatography columns
may include a filtration medium having the capacity to
fractionate any protein of interest and the peptides of the
present invention. Preferred chromatographic media would
include any gel filtration medium having a molecular frac-
tionation range suitable for the particular protein ofinterest.
Preferred media would include the G-50 or G-25 Sepha-
dex® resins which have an approximate fractionation range
of 1,500-30,000 and 100-5,000 Da, respectively. A more
preferred medium would be either the G-10 or G-15 Sepha-
dex® resins which have an approximate fractionation range
of 0-700 and 0-1500 Da,respectively.
Peptides of the present invention comprising aromatic
amino acids and multimers thereof may also be used as
protein concentration standards in reactions employing
either the Folin reagent (Lowry et al., 1951), the biuret
reaction (Coakley and James, 1978) or the bicinconinic acid
assay (Pierce Chemical Corp., Rockford,Ill.). Peptides and
multimers thereof lacking aromatic amino acids mayalso be
used as protein concentration standards in the latter two
reactions.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1A. Lysis of C1R:A2 cells after sensitization with
peptides C43 (HER-2:968-981) (MI) and C84 (HER-
2:921—979(Val) (C1)or in the absence of exogenously added
peptides (0) by CTL cultures induced in vitro with C43 and
C84 peptides. Headings indicate: donor number(e.g., 51),
numberof stimulations with peptide (e.g., 2x/3x), and the
peptide used for stimulation. Donor 51 PBMCweretested 3
weeks after the second stimulation with the C43 peptide
(total 5 weeks in culture). The studies were performed in
triplicate. The differences between individual determina-
tions were less than 10%. The differences between HER-2
peptide and control targets recognition are significant in
20-hr assays (P<0.003 for C43 and P<0.027 for C84) and are
not significant (P<0.10) in 4-hr assays. Theeffectorto target
ratio was 10:1.
FIG. 1B. Lysis of C1R:A2 cells after sensitization with
peptides C43 (HER-2:968-981) (MI) and C84 (HER-
2:921—979(Val) (C1)or in the absence of exogenously added
peptides (0) by CTL cultures induced in vitro with C43 and
C84 peptides. Headings indicate: donor number(e.g., 51),
numberof stimulations with peptide (e.g., 2x/3x), and the
peptide used for stimulation. Shownis the donor 51 PBMC
were stimulated two times with the C84 peptide and tested
3 weeksafter.
FIG. 1C. Lysis of C1R:A2 cells after sensitization with
peptides C43 (HER-2:968-981) (MI) and C84 (HER-
2:921—979(Val) (C1)or in the absence of exogenously added
peptides (0) by CTL cultures induced in vitro with C43 and
C84 peptides. Headings indicate: donor number(e.g., 51),
numberof stimulations with peptide (e.g., 2x/3x), and the
peptide used for stimulation. Shownis the donor 41 PBMC
stimulated two times with C84.
FIG. 2A. Ag specificity of the 41.CD8* CTLline. C1R:A2
cells were pre-pulsed with either HER-2 peptides or control
MUC-1peptides before being incubated with effectors. The
effector to target ratio was 10:1. C1R:Al and C1R:A3
targets were pre-pulsed with the same peptides in the same
conditions as C1R:A2 cells. Results for C1R:Al and
C1R:A3 show the difference between specific lysis of targets
preincubated with peptides and control C1R:A1 and
C1R:A3 targets. Specific lysis of control C1R:A1 and
C1R:A3 cells was less than 10% at the same E:T ratio.
Shownin FIG. 2A are results after 4 hrs’ incubation.
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FIG.2B.Agspecificity of the 41.CD8* CTLline. C1R:A2
cells were pre-pulsed with either HER-2 peptides or control
MUC-1 peptides before being incubated with effectors. The
effector to target ratio was 10:1. C1R:Al and C1R:A3
targets were pre-pulsed with the same peptides in the same
conditions as C1R:A2 cells. Results for C1R:Al and
C1R:A3 show the difference between specific lysis of targets
preincubated with peptides and control C1R:A1 and
C1R:A3 targets. Specific lysis of control C1R:A1 and
C1R:A3 cells was less than 10% at the same E:T ratio.
Shownin FIG. 2B are results after 20 hrs incubation.
FIG. 3A.Lysis of fresh isolated ovarian tumor OVA-16
(HLA-A2*, HER-2”*") cells by the donor 41 CD8*cell line.
Target lysis was determined in 5-hr (1) and 20-hr(MM)assays
in the same study against both targets.
FIG.3B.Lysis of fresh isolated ovarian tumor K562 cells
by the donor 41 CD8*cell line. Target lysis was determined
in 5-br (CZ) and 20-hr (MM) assays in the same study against
both targets.
FIG.3C.Lysis by 41.CD8* CTL of HLA-A2* HER-2”2",
HER-2’°” ovarian tumors and HLA-A3* HER-2’8*
(SKOV3) ovarian and HLA-Al1* HER-2”** (SKBr3)
breast tumor lines. C1R:A2 and XX Cr cells were negative
control targets.
FIG. 4A. Target specificity of the 41.CD8* CTL were
tested for the ability to lyse 5*Cr-labeled OVA-16 at an E:T
ratio of 10:1. C1R:A2 cells (A2.1) were incubated with
synthetic peptides (D125, C43, C85), washed, and used in
cold target inhibition studies at a cold:hot ratio of 2:1.
Cytotoxicity studies were performed for 5 hr. Results rep-
resent the mean of three determinations. The variability
between samples was less than 10%. The differences
between determination are statistically significant (P<0.03)
as determined by Student’s t test. Percentage inhibition is
indicated in parentheses.
FIG. 4B. Target specificity of the 41.CD8* CTL were
tested for the ability to lyse °'Cr-labeled OVA-16 at an E:T
ratio of 10:1. C1R:A2 cells (A2.1) were incubated with
synthetic peptides (D125, C43, C85), washed, and used in
cold target inhibition studies at a cold:hot ratio of 2:1.
Cytotoxicity studies were performed for 20 hr. Results
represent the mean of three determinations. The variability
between samples was less than 10%. The differences
between determination are statistically significant (P<0.03)
as determined by Student’s t test. Percentage inhibition is
indicated in parentheses.
FIG. 5A. Effects of HER-2 peptides on reactivity of
MA2.1 mAb with T2 cells. Fluorescence analysis and deter-
mination of FL1 were performed as described (Stausset al.,
1992). Peptides were added to T2 cells at 50 ug/ml (final
concentration). After overnight culture, in IMDM-FCS,cells
were washed and the levels of HLA-A2 expression were
determined using HLA-A2 specific mAb. Control indicates
that no exogenous peptides was added in the T2 cultures.
D98, D160, and D169 are control peptides which do not
contain HLA-A2 anchors in correct positions.
FIG. 5B. Effects of HER-2 peptides on reactivity
BB7.2 mAb with T2 cells. Studies were performed
described in the legend to FIG. 5A.
FIG. 5C. Effects of HER-2 peptides on reactivity
MA2.1 mAb with T2 cells. Studies were performed
described in the legend to FIG. 5A.
FIG. 5D. Effects of HER-2 peptides on reactivity
BB7.2 mAb with T2 cells. Studies were performed
described in the legend to FIG. 5A.
FIG.6. Effects of Folate Binding Protein (FBP) peptides
on reactivity of MA2.1 mAb with T2 cells. Experimental
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conditions as described in the legend to FIG. 5A. Control
column indicates that T2 cells were cultured in the absence
of peptide.
FIG. 7A. Surface phenotype of T-cells from PBMC cul-
tures stimulated with HER-2 peptide D97. Fresh isolated
PBMCfrom healthy volunteers were induced in vitro with
HER-2 peptides. T-cell surface phenotypes were determined
after one (1) and two (2) stimulations with the same peptide.
Immunofluorescence analysis was performed as described in
the Materials and methods. Symbols indicate (02—o) CD3*
cells, (HH) CD8*cells, and ((—1) CD4*cells.
FIG. 7B. Surface phenotype of T-cells from PBMCcul-
tures stimulated with HER-2 peptide D121. Studies were
performed as described in the legend to FIG. 7A.
FIG. 7C. Surface phenotype of T-cells from PBMCcul-
tures stimulated with HER-2 peptide C85. Studies were
performed as described in the legend to FIG. 7A.
FIG. 8A. CTL induction by HER-2 D97 peptide. PBMC
from donor 20 were induced in vitro with mock stimulated
medium only (20.C.2). After two cyclesof stimulation CTL
activity was determined in a 4 h *'Cr release assay using as
targets C1R:A2 cells pulse-labelled with the indicated pep-
tides (D97, D9, D99) or in the absence of peptide (none).
FIG. 8B. CTL induction by HER-2 D97 peptide. PBMC
from donor 20 were induced in vitro with D97 (20.D97.2),
at a ratio of 3:1. Studies were performed as described in the
legend to FIG. 8A.
FIG. 8C. CTL induction by HER-2 D97 peptide. PBMC
from donor 20 were induced in vitro with D97 (20.D97.2),
at a ratio of 6:1. Studies were performed as described in the
legend to FIG. 8A.
FIG. 9A. CTL induction by HER-2 peptides D96 and
D97. PBMCfrom donor 20 were stimulated two times with
D96 (20.D96.2). CTLactivity was determined in a 4 h *Cr
release assay using as targets C1R:A2 cells without addition
of exogenous peptide (control) or pulse-labelled with D96
(CZ), D97 (@), or NKsensitive targets K562 cells were used
as an additional control.
FIG. 9B. CTL induction by HER-2 control peptide D95
(¥) peptides. NK sensitive targets K562 cells were used as
an additional control.
FIG. 9C. CTL induction by HER-2 peptides. PBMC from
donor 30 were induced with D97 peptide (30.D97.1). Seven
days later CTL activity of these cells was determined using
as targets the peptide used for stimulation (D97) or two
HLA-A2 binding peptides with unrelated sequence D113
and D119, as specificity controls.
FIG. 10A. CTL induction by HER-2 peptide D113.
PBMC from three healthy donors (20, 25 and 30) were
induced with D113 peptide. Each culture was restimulated
with D113 once. One week later CTL activity was deter-
mined using as targets C1R:A2 cells pulsed with D113. The
effectors are designated as 20.113.2, 25.113.2 and 30.113.2
to indicate the donor number, the peptide symbol and the
numberof stimulations with peptide. Experimental condi-
tions were as described in Example 2 and the legends to FIG.
8A and FIG. 9A. E:T ratios were 20:1 (heavy stripes) and
10:1 (medium stripes).
FIG. 10B. CTL induction by HER-2 peptide D113. PBMC
from three healthy donors (20, 25 and 30) were induced with
D113 peptide. Each culture was restimulated with D113
once. One weeklater CTL activity was determined using as
targets C1R:A2 cells pulsed with control D119 peptide. The
effectors are designated as 20.113.2, 25.113.2 and 30.113.2
to indicate the donor number, the peptide symbol and the
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number of stimulations with peptide. Experimental condi-
tions wereas described in Example 2 and the legendsto FIG.
8A and FIG. 9A. E:T ratios were 20:1 (heavy stripes) and
10:1 (medium stripes).
FIG. 11A. CTL induction by HER-2 peptides D121 and
D119. PBMC from a healthy donor (20) were induced with
D121:HER-2:392-410 or D119:HER-2:402-410 by stimu-
lating with the peptides twice (20.121.2) or once (25.121.1
and 25.119.1 respectively). CTL activity was determined
using C1R:A2 targets pulsed either with the Ag of interest
(D119) or control peptides D95, D99, D97, C85 (Table 5).
E:T ratios were 20:1 (heavy stripes), 10:1 (medium stripes)
and 3:1 (light stripes).
FIG. 11B. CTL induction by HER-2 peptides D121 and
D119. PBMC from a healthy donor (25) were induced with
D121:HER-2:392-410 or D119:HER-2:402-410 by stimu-
lating with the peptides once (25.121.1). CTL activity was
determined using C1R:A2 targets pulsed either with the Ag
of interest (D119) or control peptides D95, D99, D97, C85
(Table 5). E:T ratios were 20:1 (heavy stripes), 10:1
(medium stripes) and 3:1 (light stripes).
FIG. 11C. CTL induction by HER-2 peptides D121 and
D119. PBMC from a healthy donor (25) were induced with
D121:HER-2:392-410 or D119:HER-2:402-410 by stimu-
lating with the peptides once (25.119.1). CTL activity was
determined using C1R:A2 targets pulsed either with the Ag
of interest (D119) or control peptides D95, D99, D97, C85
(Table 5). E:T ratios were 20:1 (heavy stripes), 10:1
(medium stripes) and 3:1 (light stripes).
DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS
1. Molecular Therapies for Cancer
Development of molecular therapies for cancer have
historically focused on specific recognition of Ags by cel-
lular immune effectors. The present invention discloses
novel strategies aimed at identification of peptide targets for
CTLs, and generation of T-cell immunity against specific
epitopes (for a review of T-cell specific immunity, see, e.g.,
Ioannides et al., 1992; Houbiers et al., 1993).
To achieve this, the present invention provides novel
naturally- and synthetically-derived peptides which bind
human leucocyte antigen-(HLA) class I heavy chains.
Appropriate criteria for epitope selection in vitro have been
defined. Using HER-2 protein (which has been proposed as
a candidate for an anti-tumor immuneresponsein breast and
ovarian cancer) these novel peptides have been identified,
isolated away from intact HER-2 protein and characterized.
Additionally, synthetic peptides based on immunogenic
epitopes of the HER-2 protein have also been produced.
Although the dominant anchors for peptide binding to
HLA-A2 are Leu (P2) and Val (P9), a number ofresidues
with similar charge and side chains such as Ile and Met were
identified in CTL epitopes from viral proteins (Falk et al.,
1991; Bednarek et al. 1991). Analysis of the HER-2
polypeptide sequence identified a large number of nonapep-
tides meeting these criteria (Table 1). With few exceptions,
all HLA-A2 binding peptides identified in the present inven-
tion contain Rothbard’s epitope-motifs. In a few instances,
however, the peptide sequence contained between HLA-A2
anchors matched or overlapped with amphiphilic areas.
Using more stringent selection criteria, in which only
Leu/Ile were accepted at amino acid position 2 of the peptide
(AA,) and at least one additional anchor was required,
seventeen novel sequences were found, 10 of which con-
tained Leu and Val at AA, and AA, respectively. Most of
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these sequences (shownin Table 2) were adjacent to poten-
tial amphiphilic sites.
Because it is well-known that not all HLA-A2 anchor-
containing peptides are antigenic, and that it was generally
considered not possible to generate antigens from very short
peptide sequences(such as,e.g., peptides shorter than eight
amino acids) the discovery by the inventors that these
nonameric peptides both recognized CTLs,stimulated them,
and produced an immune response was indeed a surprising
discovery.
Three criteria of epitope selection and identified the
effects of peptide length and presence of anchors on reac-
tivity of HLA-A2 with MA2.1 mAb. MA2.1 mAbrecog-
nizes an epitope made of residues 62-65 of the a1 helix
whichis left to the center of the binding site on HLA-A2
(Santon-Aguadoet al., 1988). Therefore exogenous peptide
binding to HLA-A2 mayhavethree potential consequences:
(a) induction of a conformational epitope by binding to an
‘empty’ HLA-A2 molecule,or displacing a pre-existing
endogenous peptide in which case MA2.1 mAb reac-
tivity with HLA-A2 will increase;
(b) prevention of reactivity of MA2.1 with its epitope
either by obscuring residues with which the mAb may
interact or interfering with mAbepitope interaction, in
which case MA2.1 mAbreactivity with its epitope will
decrease (Hogquist et al., 1993); and,
(c) no effect in reactivity of MA2.1 mAb with HLA-A2 in
which case the exogenous added peptide may displace
the existing endogenouspeptide, but the conformation
of the ‘face’ made of a1-peptide-c2 will not change. In
this case conformational changes on the MHC heavy
chain may be detected in a different position using
another mAb such as BB7.2 which interacts with an
epitope containing W(108) (Salter et al., 1987).
Another surprising aspect of the invention was the fact
that when long peptides (such as, e.g., peptides longer than
20 amino acids) were used which contained within their
sequences peptide sequences which are disclosed herein,
these >20 amino acid peptides failed to induce changes in
FL1 while the novel compositions disclosed herein, effec-
tively induced FL1 changes. This suggests that peptides >20
amino acids (1) either fail to bind to MHC heavy chain
because of low affinity, (2) fail to be processed to shorter
peptides because of either absence of extracellular proteases
secreted by T2 cells or (3) lack the correct sites in the
substrate for processing by extracellular proteases.
The highest increase in FL1 was induced by a D113
analog containing G (P1) replacing the bulky and hydro-
philic H (P1), suggesting that residues at P1 mayinterfere
either with mAbor peptide binding. Val (P9) appeared to be
important for MA2.1 epitope induction because substitution
M-V(P9) induced an increase in FL1 compared with the
wild-type nonapeptide C85 (971-979).
The D97 reactive CTLs identified, as well as the previ-
ously demonstrated C85 reactive CTLs, indicate that T-cells
reactive with these epitopes are not clonally deleted, while
the possible anergicstate of self-reactive CTLs from periph-
eral blood may have been overcome by using PBMCat high
density as APC. The use of PBMC as APC may have
selective advantages over T2 or C1R:A2 used in other
studies (Fisk et al., 1994; Houbiers et al., 1993). First, a
number of cells from PBMC can either present Ag, or
release lymphokines, or in general provide help for CTL
induction; second, they reflect closer the situation encoun-
tered during in vivo vaccination with tumor peptides than
T2/C1R:A2 cells; and third, induction of peptide reactive
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T-cell may not only identify epitopes able to induce a
response to a tumor Ag but also re-stimulate in vivo primed
T-cells. These cells can either recognize, or cross-react with
epitopes from HER-2 or from other proteins which mimic
the corresponding HER-2 epitopes; fourth, by determining
the frequency of such responses among healthy HLA-A2*
donors, this may allow identification of changes in the
responder frequency in breast and ovarian cancer patients
with HER-2 high and HER-2 low expression on their
tumors.
Nodirect correlation could be demonstrated between the
ability of these peptides to affect the MA2.1 epitopes and
either their ability to stimulate lymphocyte proliferation or
to induce in vitro CTLs specific for the peptide of interest.
Both D113 and D119 as well as longer peptides when used
as immunogen to stimulate PBMCin vitro failed to induce
a sustained Ag specific CTL response. In cytotoxicity assays,
the PBMCcultures stimulated with these peptides failed to
show preferential recognition of Ag used for stimulation. In
Example 1 it is shown that HER-2:968-981 or HER-
2:971-979 peptides can induce a CTL response in vitro.
Therefore the inability of peptides HER-2:2:48-56 and
HER-2:402-410 to induce in vitro Ag specific CTL may
reflect: (1) clonal deletion of epitope reactive CD8* CTL;(2)
anergy or suppression of specific CTL clones; or (3) inef-
ficient Ag presentation in the sense that the peptide although
increases the number of MA2.1 epitopes and apparently
stabilizes HLA-A2 its conformation does not provide effi-
cient signaling through TCR (Hogquistet al., 1993).
2. CTL Epitopes
CIL epitopes reported to date are mainly derived from
foreign (viral) proteins with little or no homology with
self-proteins. With respect to CTL responsestoself-proteins,
it is expected that T-cells expressing TCR with high affinity
for self-peptide-MHCclass I complexes are eliminated in
the thymus during development. Self-peptides eluted from
HLA-A2.1 molecules of various cell lines show residuesat
P3-P5 and P7—P8 whichare different from the sequences of
viral epitopes recognized by human CTLs. Since these
residues are likely to contact and interact with TCR, they
mayreflect peptides for which autologous T-cells are already
tolerant/anergic.
For T-cell recognizing self-epitopes to be eliminated or
anergized, a precondition exists that the peptide-MHC com-
plex is stable enough to engage a sufficient number of TCRs,
or at least more stable than other HLA-A2 peptide
complexes, where one peptide can be easily displaced by
other peptides. Consequently this would suggest that for
self-proteins with extension to HER-2,the ones that can bind
TCR with high affinity during development will be less
likely to be recognized later when expressed on a tumor
other target, than peptides that bind HLA-A2 with low
affinity, which under appropriate conditions (e.g., high pro-
tein concentration) may occupy a higher number of HLA-A2
molecules. For low-affinity peptides, modification of the
anchorsresulting in stabilization of peptide—HLA-A2 inter-
action by replacing weak with dominant anchor residues
(e.g., (P9) M-V,shouldfacilitate the reactivity of CTL with
targets expressing such antigens, because TCR interacts
mainly with the sequence P4—P8.
Tumor progression and metastasis are often associated
with overexpression of specific cellular proteins. Epitopes of
non-mutated overexpressed proteins can be targets of a
specific cellular immune response against tumor mediated
by T-cells. Moreover, when T-cell epitopes are present,
distinction between tumor immunity/autoimmunity and
unresponsiveness can be predicated on the protein concen-
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tration as a limiting factor of epitope supply. The present
inventors have demonstrated that CTLs from patients with
ovarian tumors which over-express HER-2 proto-oncogene
can recognize both autologous tumor and novel synthetic
analogs of a specific HER-2 epitopes. These epitopes were
identified in HER-2 containing nonapeptides with HLA-A2
anchors. Analysis of potential amphiphilic sites identified
natural peptides and novel synthetic peptides which surpris-
ingly affected the reactivity of conformationally-dependent
HLA-A2 specific monoclonal antibodies (mAbs), and indi-
cated specific binding of these peptides similar to that seen
for HER-2 epitopes.
3. Screening Kits
In another aspect, the present invention contemplates a
diagnostic kit for screening samples suspected of containing
HER-2/neu or neu-related polypeptides, or cells producing
such polypeptides. Said kit can contain a peptide or antibody
of the present invention. The kit can contain reagents for
detecting an interaction between an agent and a peptide or
antibody of the present invention. The provided reagent can
be radio-, fluorescently- or enzymatically-labeled. The kit
can contain a known radiolabeled agent capable of binding
or interacting with a peptide or antibody of the present
invention.
In another aspect, the present invention contemplates a
diagnostic kit for detecting CTLs. The kit comprises
reagents capable of detecting a peptide of the present
invention and a CTL. The provided reagent may also be
radio-, enzymatically-, or fluorescently-labeled. The kit can
contain a radiolabeled peptide capable of binding to or
interacting with a CTL, or may contain a radiolabeled
antibody capable of binding to or interacting with a peptide
of the present invention which in turn interacts with a CTL.
The kit can contain a polynucleotide probe from about 15 to
60 nucleotides that encodes a peptide of the present inven-
tion or any of their complements. The kit can contain an
antibody immunoreactive with a peptide of the present
invention.
The reagentof the kit can be providedasa liquid solution,
attached to a solid support or as a dried powder. Preferably,
whenthe reagent is provided in a liquid solution, the liquid
solution is an aqueoussolution. Preferably, when the reagent
providedis attached to a solid support, the solid support can
be chromatograph media, a test plate having a plurality of
wells, or a microscope slide. When the reagent provided is
a dry powder, the powder can be reconstituted by the
addition of a suitable solvent, that may be provided.
4. Immunodetection Kits
In still further embodiments, the present invention con-
cerns immunodetection methods and associated kits. It is
proposed that the CTL-stimulating peptides of the present
invention may be employed to detect antibodies having
reactivity therewith, or, alternatively, antibodies prepared in
accordance with the present invention, may be employed to
detect CTLs or neu-related epitope-containing peptides. In
general, these methods will includefirst obtaining a sample
suspected of containing such a protein, peptide or antibody,
contacting the sample with an antibody or peptide in accor-
dance with the present invention, as the case may be, under
conditions effective to allow the formation of an
immunocomplex, and then detecting the presence of the
immunocomplex.
In general, the detection of immunocomplex formation is
quite well knownin the art and may be achieved through the
application of numerous approaches. For example, the
present invention contemplates the application of ELISA,
RIA, immunoblot (e.g., dot blot), indirect immunofluores-
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cence techniques and the like. Generally, immunocomplex
formation will be detected through the use of a label, such
as a radiolabel or an enzyme tag (such as alkaline
phosphatase, horseradish peroxidase,or the like). Of course,
one may find additional advantages through the use of a
secondary binding ligand such as a second antibody or a
biotin/avidin ligand binding arrangement, as is knownin the
art.
For diagnostic purposes, it is proposed that virtually any
sample suspected of comprising either the HER-2/neu pep-
tide or neu-related peptides or antibody sought to be
detected, as the case may be, may be employed. Exemplary
samples include clinical samples obtained from a patient
such as blood or serum samples, ear swabs, sputum samples,
middle ear fluid or even perhaps urine samples may be
employed. Furthermore, it is contemplated that such
embodiments may have application to non-clinical samples,
such as in thetitering of antigen or antibody samples, in the
selection of hybridomas, andthe like.
In related embodiments, the present invention contem-
plates the preparation of kits that may be employedto detect
the presence of HER-2/neu or neu-related proteins or pep-
tides and/or antibodies in a sample. Generally speaking, kits
in accordance with the present invention will include a
suitable CTL-stimulating peptide or an antibody directed
against such a protein or peptide, together with an immu-
nodetection reagent and a meansfor containing the antibody
or antigen and reagent. The immunodetection reagent will
typically comprise a label associated with the antibody or
antigen, or associated with a secondary binding ligand.
Exemplary ligands might include a secondary antibody
directed against the first antibody or antigen or a biotin or
avidin (or streptavidin) ligand having an associated label. Of
course, as noted above, a number of exemplary labels are
known in the art and all such labels may be employed in
connection with the present invention.
The container means will generally include a vial into
which the antibody, antigen or detection reagent may be
placed, and preferably suitably aliquotted. The kits of the
present invention will also typically include a means for
containing the antibody, antigen, and reagent containers in
close confinement for commercial sale. Such containers may
include injection or blow-molded plastic containers into
which the desired vials are retained.
5. ELISAs
ELISAs may be used in conjunction with the invention. In
an ELISA assay, proteins or peptides incorporating dgA
antigen sequences are immobilized onto a selected surface,
preferably a surface exhibiting a protein affinity such as the
wells of a polystyrene microtiter plate. After washing to
remove incompletely adsorbed material, it is desirable to
bind or coat the assay plate wells with a nonspecific protein
that is knownto be antigenically neutral with regard to the
test antisera such as bovine serum albumin (BSA), casein or
solutions of milk powder. This allows for blocking of
nonspecific adsorption sites on the immobilizing surface and
thus reduces the background caused by nonspecific binding
of antisera onto the surface.
After binding of antigenic material to the well, coating
with a non-reactive material to reduce background, and
washing to remove unbound material, the immobilizing
surface is contacted with the antisera or clinical or biological
extract to be tested in a manner conducive to immune
complex (antigen/antibody) formation. Such conditions
preferably include diluting the antisera with diluents such as
BSA,bovine gamma globulin (BGG) and phosphate buff-
ered saline (PBS)/Tween®. These added agents also tend to
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assist in the reduction of nonspecific background. The
layered antisera is then allowed to incubate for from 2 to 4
hours, at temperatures preferably on the order of about 25°
to about 27° C. Following incubation, the antisera-contacted
surface is washed so as to remove non-immunocomplexed
material. A preferred washing procedure includes washing
with a solution such as PBS/Tween®, or borate buffer.
Following formation of specific immunocomplexes
between the test sample and the bound antigen, and subse-
quent washing, the occurrence and even amount of immu-
nocomplex formation may be determined by subjecting
same to a second antibody having specificity for the first. To
provide a detecting means, the second antibody will pref-
erably have an associated enzymethat will generate a color
development upon incubating with an appropriate chro-
mogenic substrate. Thus, for example, one will desire to
contact and incubate the antisera-bound surface with a
urease or peroxidase-conjugated anti-human IgG for a
period of time and under conditions which favor the devel-
opment of immunocomplex formation (e.g., incubation for 2
hours at room temperature in a PBS-containing solution
such as PBS-Tween®).
After incubation with the second enzyme-tagged
antibody, and subsequent to washing to remove unbound
material, the amountof label is quantified by incubation with
a chromogenic substrate such as urea and bromocresol
purple or 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic
acid [ABTS] and H,0,, in the case of peroxidase as the
enzymelabel. Quantification is then achieved by measuring
the degree of color generation, e.g., using a visible spectra
spectrophotometer.
6. Epitopic Core Sequences
The present inventionis also directed to protein or peptide
compositions,free from total cells and other peptides, which
comprise a purified protein or peptide which incorporates an
epitope that is immunologically cross-reactive with one or
more anti-HER-2/neu antibodies.
As used herein, the term “incorporating an epitope(s) that
is immunologically cross-reactive with one or more anti-
HER-2/neu antibodies” is intended to refer to a peptide or
protein antigen which includes a primary, secondary or
tertiary structure similar to an epitope located within a
HER-2 proto-oncogene polypeptide. The level of similarity
will generally be to such a degree that monoclonal or
polyclonal antibodies directed against the HER-2 polypep-
tide will also bindto, react with, or otherwise recognize, the
cross-reactive peptide or protein antigen. Various immu-
noassay methods may be employed in conjunction with such
antibodies, such as, for example, Western blotting, ELISA,
RIA,and the like, all of which are known to those of skill
in theart.
The identification of CTL-stimulating immunodominant
epitopes, and/ortheir functional equivalents, suitable for use
in vaccines is a relatively straightforward matter. For
example, one may employ the methods of Hopp,as taught
in U.S. Pat. No. 4,554,101, incorporated herein by reference,
which teaches the identification and preparation of epitopes
from amino acid sequences on the basis of hydrophilicity.
The methods described in several other papers, and software
programsbased thereon,can also be used to identify epitopic
core sequences(see, for example, Jameson and Wolf, 1988;
Wolf et al., 1988; U.S. Pat. No. 4,554,101). The amino acid
sequence of these “epitopic core sequences” may then be
readily incorporated into peptides, either through the appli-
cation of peptide synthesis or recombinant technology.
Preferred peptides for use in accordance with the present
invention will generally be on the order of 8 to 20 amino
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acids in length, and more preferably about 8 to about 15
amino acids in length. It is proposed that shorter antigenic
CTL-stimulating peptides will provide advantages in certain
circumstances, for example, in the preparation of vaccines or
in immunologic detection assays. Exemplary advantages
include the ease of preparation and purification, the rela-
tively low cost and improved reproducibility of production,
and advantageous biodistribution.
It is proposed that particular advantages of the present
invention may be realized through the preparation of syn-
thetic peptides which include modified and/or extended
epitopic/immunogenic core sequences which result in a
“universal” epitopic peptide directed to HER-2/neu and
neu-related sequences. These epitopic core sequences are
identified herein in particular aspects as hydrophilic regions
of the HER-2/neu proto-oncogene polypeptide antigen.It is
proposed that these regions represent those which are most
likely to promote T-cell or B-cell stimulation, and, hence,
elicit specific antibody production.
An epitopic core sequence, as used herein,is a relatively
short stretch of amino acids that is “complementary” to, and
therefore will bind, antigen binding sites on transferrin-
binding protein antibodies. Additionally or alternatively, an
epitopic core sequence is one that will elicit antibodies that
are cross-reactive with antibodies directed against the pep-
tide compositions of the present invention. It will be under-
stood that in the context of the present disclosure, the term
“complementary” refers to amino acids or peptides that
exhibit an attractive force towards each other. Thus, certain
epitope core sequences of the present invention may be
operationally defined in terms of their ability to compete
with or perhaps displace the binding of the desired protein
antigen with the corresponding protein-directed antisera.
In general, the size of the polypeptide antigen is not
believed to be particularly crucial, so long as it is at least
large enough to carry the identified core sequence or
sequences. The smallest useful core sequence anticipated by
the present disclosure would generally be on the order of
about 8 amino acids in length, with sequences on the order
of 9 or 10 being more preferred. Thus, this size will
generally correspond to the smallest peptide antigens pre-
pared in accordance with the invention. However,the size of
the antigen may be larger where desired, so long as it
contains a basic epitopic core sequence.
The identification of epitopic core sequences is known to
those of skill in theart, for example, as described in U'S. Pat.
No. 4,554,101, incorporated herein by reference, which
teaches the identification and preparation of epitopes from
amino acid sequences on the basis of hydrophilicity.
Moreover, numerous computer programs are available for
use in predicting antigenic portions of proteins (see e.g.,
Jameson & Wolf, 1988; Wolf et al., 1988). Computerized
peptide sequence analysis programs (e.g., DNAStar
Software, DNAStar, Inc., Madison, Wis.) may also be useful
in designing synthetic peptides in accordance with the
present disclosure.
Syntheses of epitopic sequences, or peptides which
include an antigenic epitope within their sequence, are
readily achieved using conventional synthetic techniques
such as the solid phase method (e.g., through the use of
commercially available peptide synthesizer such as an
Applied Biosystems Model 430A Peptide Synthesizer). Pep-
tide antigens synthesized in this manner may then beali-
quotted in predetermined amounts and stored in conven-
tional manners, such as in aqueoussolutions or, even more
preferably, in a powder or lyophilized state pending use.
In general, due to the relative stability of peptides, they
may be readily stored in aqueous solutions for fairly long
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periods of time if desired, e.g., up to six months or more, in
virtually any aqueous solution without appreciable degra-
dation or loss of antigenic activity. However, where
extended aqueous storage is contemplated it will generally
be desirable to include agents including buffers such as Tris
or phosphate buffers to maintain a pH of about 7.0 to about
7.5. Moreover, it may be desirable to include agents which
will inhibit microbial growth, such as sodium azide or
Merthiolate. For extended storage in an aqueousstate it will
be desirable to store the solutions at 4° C., or more
preferably, frozen. Of course, where the peptides are stored
in a lyophilized or powdered state, they may be stored
virtually indefinitely, e.g., in metered aliquots that may be
rehydrated with a predetermined amount of water
(preferably distilled) or buffer prior to use.
7. Immunoprecipitation
The antibodies of the present invention are particularly
useful for the isolation of antigens by immunoprecipitation.
Immunoprecipitation involves the separation of the target
antigen component from a complex mixture, and is used to
discriminate or isolate minute amounts of protein. For the
isolation of membraneproteins cells must be solubilized into
detergent micelles. Nonionic salts are preferred, since other
agents such as bile salts, precipitate at acid pH or in the
presence of bivalent cations.
In an alternative embodimentthe antibodies of the present
invention are useful for the close juxtaposition of two
antigens. Thisis particularly useful for increasing the local-
ized concentration of antigens, e.g. enzyme-substrate pairs.
8. Western Blots
The compositions of the present invention will find great
use in immunoblotor western blot analysis. The anti-peptide
antibodies may be used as high-affinity primary reagents for
the identification of proteins immobilized onto a solid sup-
port matrix, such as nitrocellulose, nylon or combinations
thereof. In conjunction with immunoprecipitation, followed
by gel electrophoresis, these may be used as a single step
reagent for use in detecting antigens against which second-
ary reagents used in the detection of the antigen cause an
adverse background. This is especially useful when the
antigens studied are immunoglobulins (precluding the use of
immunoglobulins binding bacterial cell wall components),
the antigens studied cross-react with the detecting agent, or
they migrate at the same relative molecular weight as a
cross-reacting signal.
Immunologically-based detection methodsfor use in con-
junction with Western blotting include enzymatically-,
radiolabel-, or fluorescently-tagged secondary antibodies
against the toxin moiety are considered to be of particular
use in this regard.
9. Vaccines
The present invention contemplates vaccines for use in
both active and passive immunization embodiments. Immu-
nogenic compositions, proposed to be suitable for use as a
vaccine, may be prepared mostreadily directly from immu-
nogenic CTL-stimulating peptides prepared in a manner
disclosed herein. Preferably the antigenic material is exten-
sively dialyzed to remove undesired small molecular weight
molecules and/or lyophilized for more ready formulation
into a desired vehicle.
The preparation of vaccines which contain peptide
sequences as active ingredients is generally well understood
in the art, as exemplified by U.S. Pat. Nos. 4,608,251;
4,601,903; 4,599,231; 4,599,230; 4,596,792; and 4.578,770,
all incorporated herein by reference. Typically, such vac-
cines are prepared as injectables. Either as liquid solutions
or suspensions: solid forms suitable for solution in, or
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suspensionin, liquid prior to injection mayalso be prepared.
The preparation may also be emulsified. The active immu-
nogenic ingredient is often mixed with excipients which are
pharmaceutically acceptable and compatible with the active
ingredient. Suitable excipients are, for example, water,
saline, dextrose, glycerol, ethanol, or the like and combina-
tions thereof. In addition, if desired, the vaccine may contain
minor amounts of auxiliary substances such as wetting or
emulsifying agents, pH buffering agents, or adjuvants which
enhance the effectiveness of the vaccines.
Vaccines may be conventionally administered
parenterally, by injection, for example, either subcutane-
ously or intramuscularly. Additional formulations which are
suitable for other modes of administration include supposi-
tories and, in some cases, oral formulations. For
suppositories, traditional binders and carriers may include,
for example, polyalkalene glycols or triglycerides: such
suppositories may be formed from mixtures containing the
active ingredient in the range of about 0.5% to about 10%,
preferably about 1 to about 2%. Oral formulations include
such normally employed excipients as, for example, phar-
maceutical grades of mannitol, lactose, starch, magnesium
stearate, sodium saccharine, cellulose, magnesium carbon-
ate and the like. These compositions take the form of
solutions, suspensions, tablets, pills, capsules, sustained
release formulations or powders and contain about 10 to
about 95% ofactive ingredient, preferably about 25 to about
70%.
The peptides of the present invention may be formulated
into the vaccine as neutral or salt forms. Pharmaceutically-
acceptable salts, include the acid addition salts (formed with
the free amino groups of the peptide) and those which are
formed with inorganic acids such as, for example, hydro-
chloric or phosphoric acids, or such organic acids as acetic,
oxalic, tartaric, mandelic, and the like. Salts formed with the
free carboxyl groups may also be derived from inorganic
bases such as, for example, sodium, potassium, ammonium,
calcium, or ferric hydroxides, and such organic bases as
isopropylamine, trimethylamine, 2-ethylamino ethanol,
histidine, procaine, and the like.
The vaccines are administered in a manner compatible
with the dosage formulation, and in such amountas will be
therapeutically effective and immunogenic. The quantity to
be administered depends on the subject to be treated,
including, e.g., the capacity of the individual’s immune
system to synthesize antibodies, and the degree of protection
desired. Precise amounts of active ingredient required to be
administered depend on the judgment of the practitioner.
However, suitable dosage ranges are of the order of several
hundred microgramsactive ingredient per vaccination. Suit-
able regimes for initial administration and booster shots are
also variable, but are typified by an initial administration
followed by subsequent inoculations or other administra-
tions.
The mannerof application may be varied widely. Any of
the conventional methodsfor administration of a vaccine are
applicable. These are believed to include oral application on
a solid physiologically acceptable base or in a physiologi-
cally acceptable dispersion, parenterally, by injection or the
like. The dosage of the vaccine will depend on the route of
administration and will vary according to the size of the
host.
Various methods of achieving adjuvant effect for the
vaccine includes use of agents such as aluminum hydroxide
or phosphate (alum), commonly used as about 0.05 to about
0.1% solution in phosphate buffered saline, admixture with
synthetic polymers of sugars (Carbopol®) used as an about
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0.25% solution, aggregation of the protein in the vaccine by
heat treatment with temperatures ranging between about 70°
to about 101° C. for a 30-second to 2-minute period,
respectively. Aggregation by reactivating with pepsintreated
(Fab) antibodies to albumin, mixture with bacterial cells
such as C. parvum or endotoxins or lipopolysaccharide
components of Gram-negative bacteria, emulsion in physi-
ologically acceptable oil vehicles such as mannide
monooleate (Aracel A) or emulsion with a 20% solution of
a perfluorocarbon (Fluosol-DA®)used as a block substitute
may also be employed.
In many instances, it will be desirable to have multiple
administrations of the vaccine, usually not exceeding six
vaccinations, more usually not exceeding four vaccinations
and preferably one or more, usually at least about three
vaccinations. The vaccinations will normally be at from two
to twelve week intervals, more usually from three to five
weekintervals. Periodic boosters at intervals of 1-5 years,
usually three years, will be desirable to maintain protective
levels of the antibodies. The course of the immunization
may be followed byassays for antibodies for the supernatant
antigens. The assays may be performed by labeling with
conventional labels, such as radionuclides, enzymes,
fluorescents, and the like. These techniques are well known
and may be found in a widevariety of patents, such as US.
Patent Nos. 3,791,932; 4,174,384 and 3,949,064, as illus-
trative of these types of assays.
10. DNA Segments Encoding Novel Peptides
The present invention also concerns DNA segments, that
can be isolated from virtually any mammalian source, that
are free from total genomic DNAandthat encode the novel
peptides disclosed herein. DNA segments encoding these
peptide species may prove to encode proteins, polypeptides,
subunits, functional domains, and the like of HER-2/neu-
related or other non-related gene products. In addition these
DNAsegments may be synthesized entirely in vitro using
methods that are well-known to those of skill in the art.
As used herein, the term “DNAsegment”refers to a DNA
molecule that has been isolated free of total genomic DNA
of a particular species. Therefore, a DNA segment encoding
a CTL-stimulating peptide refers to a DNA segment that
contains CTL-stimulating coding sequences yet is isolated
away from,or purified free from, total genomic DNAofthe
species from which the DNA segmentis obtained. Included
within the term “DNA segment”, are DNA segments and
smaller fragments of such segments, and also recombinant
vectors, including, for example, plasmids, cosmids,
phagemids, phage, viruses, and the like.
Similarly, a DNA segment comprising an isolated or
purified CTL-stimulating peptide-encoding gene refers to a
DNA segment which may include in addition to peptide
encoding sequences, certain other elements such as, regu-
latory sequences, isolated substantially away from other
naturally occurring genes or protein-encoding sequences. In
this respect, the term “gene” is used for simplicity to refer
to a functional protein-, polypeptide- or peptide-encoding
unit. As will be understood bythosein theart, this functional
term includes both genomic sequences, cDNA sequences
and smaller engineered gene segments that express, or may
be adapted to express, proteins, polypeptides or peptides.
“Tsolated substantially away from other coding
sequences” meansthat the gene of interest, in this case, a
gene encoding CTL-stimulating peptides, forms the signifi-
cant part of the coding region of the DNA segment, and that
the DNA segment does not contain large portions of
naturally-occurring coding DNA, such as large chromo-
somal fragments or other functional genes or cDNA coding
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regions. Of course, this refers to the DNA segment as
originally isolated, and does not exclude genes or coding
regions later added to the segment by the hand of man.
In particular embodiments, the invention concerns iso-
lated DNA segments and recombinant vectors incorporating
DNA sequences that encode a CTL-stimulating peptide
species that includes within its amino acid sequence an
amino acid sequence essentially as set forth in any of SEQ
ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ
ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ
ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13,
SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID
NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,
SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID
NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26,
SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29.
The term “a sequence essentially as set forth in any of
SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4,
SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8,
SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID
NO:13, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15,
SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID
NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22,
SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID
NO:26, SEQ ID NO:27, SEQ ID NO:28, and SEQ ID
NO:29” meansthat the sequence substantially corresponds
to a portion of the sequence of either SEQ ID NO:1, SEQ ID
NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID
NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID
NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:13,
SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID
NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,
SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID
NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27,
SEQ ID NO:28, or SEQ ID NO:29 and hasrelatively few
amino acids that are not identical to, or a biologically
functional equivalent of, the amino acids of any of these
sequences. The term “biologically functional equivalent”is
well understood in the art and is further defined in detail
herein (for example, see Preferred Embodiments).
Accordingly, sequences that have between about 70% and
about 80%, or more preferably between about 81% and
about 90%,or even more preferably between about 91% and
about 99% amino acid sequence identity or functional
equivalence to the aminoacids of any of SEQ ID NO:1, SEQ
ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ
ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ
ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:13,
SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID
NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,
SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID
NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27,
SEQ ID NO:28, and SEQ ID NO:29 will be sequencesthat
are “essentially as set forth in any of SEQ ID NO:1, SEQ ID
NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID
NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID
NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:13,
SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID
NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,
SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID
NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27,
SEQ ID NO:28, and SEQ ID NO:29.”
It will also be understood that amino acid and nucleic acid
sequences may include additional residues, such as addi-
tional N- or C-terminal amino acids or 5' or 3' sequences,
and yetstill be essentially as set forth in one of the sequences
disclosed herein, so long as the sequence meets the criteria
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set forth above, including the maintenance of biological
protein activity where protein expression is concerned. The
addition of terminal sequencesparticularly applies to nucleic
acid sequences that may, for example, include various
non-coding sequencesflanking either of the 5' or 3' portions
of the coding region or may include various internal
sequences, i.e., introns, which are known to occur within
genes.
The nucleic acid segments of the present invention,
regardless of the length of the coding sequenceitself, may
be combined with other DNA sequences, such as promoters,
polyadenylation signals, additional restriction enzymesites,
multiple cloning sites, other coding segments, and the like,
such that their overall length may vary considerably. It is
therefore contemplated that a nucleic acid fragment of
almost any length may be employed, with the total length
preferably being limited by the ease of preparation and use
in the intended recombinant DNA protocol. For example,
nucleic acid fragments may be prepared that include a short
contiguous stretch encoding either of the peptide sequences
disclosed in any of SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID
NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ
ID NO:12, SEQ ID NO:13, SEQ ID NO:13, SEQ ID NO:14,
SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID
NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21,
SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID
NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28,
and SEQ ID NO:29,or that are identical to or complemen-
tary to DNA sequences which encode any of the peptides
disclosed in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3,
SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7,
SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID
NO:12, SEQ ID NO:13, SEQ ID NO:13, SEQ ID NO:14,
SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID
NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21,
SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID
NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28,
and SEQ ID NO:29, and particularly those DNA segments
disclosed in SEQ ID NO:51, SEQ ID NO:52, SEQ ID
NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56,
SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID
NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63 and
SEQ ID NO:64. For example, DNAsequences such as about
14 nucleotides, and that are up to about 1,000, about 500,
about 200, about 100, about 50, and about 25 base pairs in
length (including all intermediate lengths) are also contem-
plated to be useful.
It will be readily understood that “intermediate lengths”,
in these contexts, means any length between the quoted
ranges, such as 14, 15, 16, 17, 18, 19, 20, etc.; 21, 22, 23,
etc.; 30, 31, 32,etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103,
etce.; 150, 151, 152, 153, etc.; including all integers through
the 200-500; 500-1,000; 1,000-—2,000; 2,000-3,000;
3,000-5,000; and up to and including sequences of about
10,000 nucleotides and the like.
It will also be understoodthat this inventionis not limited
to the particular nucleic acid sequences which encode pep-
tides of the present invention, or which encode the amino
acid sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID
NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID
NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ
ID NO:12, SEQ ID NO:13, SEQ ID NO:13, SEQ ID NO:14,
SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID
NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21,
SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID
NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28,
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and SEQ ID NO:29, including those DNA sequences which
are particularly disclosed in SEQ ID NO:51, SEQ ID NO:52,
SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID
NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59,
SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID
NO:63 and SEQ ID NO:64. Recombinant vectors and iso-
lated DNA segments may therefore variously include the
peptide-coding regions themselves, coding regions bearing
selected alterations or modifications in the basic coding
region, or they may encode larger polypeptides that never-
theless include these peptide-coding regions or may encode
biologically functional equivalent proteins or peptides that
have variant amino acids sequences.
The DNA segments of the present invention encompass
biologically-functional equivalent peptides. Such sequences
may arise as a consequence of codon redundancy and
functional equivalency that are known to occur naturally
within nucleic acid sequences andthe proteins thus encoded.
Alternatively, functionally-equivalent proteins or peptides
may be created via the application of recombinant DNA
technology, in which changes in the protein structure may be
engineered, based on considerations of the properties of the
amino acids being exchanged. Changes designed by man
may be introduced through the application of site-directed
mutagenesis techniques, e.g., to introduce improvements to
the antigenicity of the protein or to test mutants in order to
examine activity at the molecular level.
If desired, one may also prepare fusion proteins and
peptides, e.g., where the peptide-coding regions are aligned
within the same expression unit with other proteins or
peptides having desired functions, such as for purification or
immunodetection purposes(e.g., proteins that may be puri-
fied by affinity chromatography and enzyme label coding
regions, respectively).
Recombinant vectors form further aspects of the present
invention. Particularly useful vectors are contemplated to be
those vectors in which the coding portion of the DNA
segment, whether encoding a full length protein or smaller
peptide, is positioned under the control of a promoter. The
promoter maybein the form of the promoterthat is naturally
associated with a gene encoding peptides of the present
invention, as may be obtained byisolating the 5' non-coding
sequences located upstream of the coding segment or exon,
for example, using recombinant cloning and/or PCR™
technology, in connection with the compositions disclosed
herein.
In other embodiments, it is contemplated that certain
advantages will be gained by positioning the coding DNA
segment under the control of a recombinant, or
heterologous, promoter. As used herein, a recombinant or
heterologous promoter is intended to refer to a promoterthat
is not normally associated with a DNA segmentencoding a
CTL-stimulating peptide in its natural environment. Such
promoters may include promoters normally associated with
other genes, and/or promoters isolated from any bacterial,
viral, eukaryotic, or mammalian cell. Naturally, it will be
important to employ a promoter that effectively directs the
expression of the DNA segmentinthe cell type, organism,
or even animal, chosen for expression. The use of promoter
and cell type combinations for protein expression is gener-
ally knownto those of skill in the art of molecular biology,
for example, see Sambrook et al., 1989. The promoters
employed may be constitutive, or inducible, and can be used
under the appropriate conditions to direct high level expres-
sion of the introduced DNA segment, such as is advanta-
geous in the large-scale production of recombinant proteins
or peptides. Appropriate promoter systems contemplated for
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use in high-level expression include, but are not limited to,
the Pichia expression vector system (Pharmacia LKB
Biotechnology).
In connection with expression embodiments to prepare
recombinant proteins and peptides, it is contemplated that
longer DNA segments will most often be used, with DNA
segments encoding the entire peptide sequence being most
preferred. However, it will be appreciated that the use of
shorter DNA segments to direct the expression of CTL-
stimulating peptides or epitopic core regions, such as may be
used to generate anti-peptide antibodies,also falls within the
scope of the invention. DNA segments that encode peptide
antigens from about 8 to about 50 amino acids in length, or
more preferably, from about 8 to about 30 amino acids in
length, or even more preferably, from about 8 to about 20
amino acids in length are contemplated to be particularly
useful.
In addition to their use in directing the expression of
CTL-stimulating peptides of the present invention, the
nucleic acid sequences contemplated herein also have a
variety of other uses. For example, they also have utility as
probes or primers in nucleic acid hybridization embodi-
ments. As such,it is contemplated that nucleic acid segments
that comprise a sequence region that consists ofat least a 14
nucleotide long contiguous sequence that has the same
sequence as, or is complementary to, a 14 nucleotide long
contiguous DNA segment any of SEQ ID NO:51, SEQ ID
NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55,
SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID
NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62,
SEQ ID NO:63, and SEQ ID NO:64 will find particular
utility. Longer contiguous identical or complementary
sequences, e.g., those of about 20, 30, 40, 50, 100, 200, 500,
1000 (including all intermediate lengths) and even upto full
length sequences will also be of use in certain embodiments.
The ability of such nucleic acid probes to specifically
hybridize to peptide-encoding sequences will enable them to
be of use in detecting the presence of complementary
sequences in a given sample. However, other uses are
envisioned, including the use of the sequence information
for the preparation of mutant species primers, or primers for
use in preparing other genetic constructions.
Nucleic acid molecules having sequence regions consist-
ing of contiguous nucleotide stretches of 10-14, 15-20, 30,
50, or even of 100-200 nucleotides or so, identical or
complementary to DNAsequencesof any of SEQ ID NO:51,
SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID
NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58,
SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID
NO:62, SEQ ID NO:63, and SEQ ID NO:64,are particularly
contemplated as hybridization probesfor use in, e.g., South-
ern and Northern blotting. Smaller fragments will generally
find use in hybridization embodiments, wherein the length
of the contiguous complementary region may be varied,
such as between about 10-14 and about 100 nucleotides, but
larger contiguous complementarity stretches may be used,
according to the length complementary sequences one
wishesto detect.
The use of a hybridization probe of about 10-14 nucle-
otides in length allows the formation of a duplex molecule
that is both stable and selective. Molecules having contigu-
ous complementary sequencesoverstretches greater than 10
bases in length are generally preferred, though, in order to
increase stability and selectivity of the hybrid, and thereby
improve the quality and degree of specific hybrid molecules
obtained. One will generally prefer to design nucleic acid
molecules having gene-complementary stretches of 15 to 20
contiguous nucleotides, or even longer where desired.
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Of course, fragments may also be obtained by other
techniques such as, e.g., by mechanical shearing or by
restriction enzymedigestion. Small nucleic acid segments or
fragments may be readily prepared by, for example, directly
synthesizing the fragment by chemical means, as is com-
monly practiced using an automated oligonucleotide syn-
thesizer. Also, fragments may be obtained by application of
nucleic acid reproduction technology, such as the PCR™
technology of US. Pat. Nos. 4,683,195 and 4,683,202 (each
incorporated herein by reference), by introducing selected
sequences into recombinant vectors for recombinant
production, and by other recombinant DNA techniques
generally known to those of skill in the art of molecular
biology.
Accordingly, the nucleotide sequences of the invention
may be used for their ability to selectively form duplex
molecules with complementary stretches of DNAfragments.
Depending on the application envisioned, one will desire to
employ varying conditions of hybridization to achieve vary-
ing degrees of selectivity of probe towards target sequence.
For applications requiring high selectivity, one will typically
desire to employrelatively stringent conditions to form the
hybrids, e.g., one will select relatively low salt and/or high
temperature conditions, such as provided by about 0.02 M to
about 0.15 M NaCl at temperatures of 50° C. to 70° C. Such
selective conditionstoleratelittle, if any, mismatch between
the probe and the template or target strand, and would be
particularly suitable for isolating CTL-stimulating peptide-
encoding DNA segments. Detection of DNA segments via
hybridization is well-known to those of skill in the art, and
the teachings of U.S. Pat. Nos. 4,965,188 and 5,176,995
(each incorporated herein by reference) are exemplary of the
methods of hybridization analyses. Teachings such as those
found in the texts of Maloy et al., 1993; Segal 1976;
Proskop, 1991; and Kuby, 1991, are particularly relevant.
Ofcourse, for some applications, for example, where one
desires to prepare mutants employing a mutant primerstrand
hybridized to an underlying template or where one seeks to
isolate CTL-stimulating peptide-encoding sequences from
related species, functional equivalents, or the like, less
stringent hybridization conditions will typically be needed in
order to allow formation of the heteroduplex. In these
circumstances, one may desire to employ conditions such as
about 0.15 M to about 0.9 M salt, at temperatures ranging
from about 20° C. to about 55° C. Cross-hybridizing species
can thereby be readily identified as positively hybridizing
signals with respect to control hybridizations. In any case,it
is generally appreciated that conditions can be rendered
more stringent by the addition of increasing amounts of
formamide, which serves to destabilize the hybrid duplex in
the same manner as increased temperature. Thus, hybrid-
ization conditions can be readily manipulated, and thus will
generally be a method of choice depending on the desired
results.
In certain embodiments, it will be advantageous to
employ nucleic acid sequences of the present invention in
combination with an appropriate means, such asa label, for
determining hybridization. A wide variety of appropriate
indicator means are knownin theart, including fluorescent,
radioactive, enzymatic or other ligands, such as avidin/
biotin, which are capable of giving a detectable signal. In
preferred embodiments, one will likely desire to employ a
fluorescent label or an enzyme tag, such as urease, alkaline
phosphatase or peroxidase, instead of radioactive or other
environmental undesirable reagents. In the case of enzyme
tags, calorimetric indicator substrates are knownthat can be
employed to provide a meansvisible to the human eye or
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spectrophotometrically, to identify specific hybridization
with complementary nucleic acid-containing samples.
In general, it is envisioned that the hybridization probes
described herein will be useful both as reagents in solution
hybridization as well as in embodiments employing a solid
phase. In embodiments involving a solid phase, the test
DNA(or RNA)is adsorbedor otherwise affixed to a selected
matrix or surface. Thisfixed, single-stranded nucleic acid is
then subjected to specific hybridization with selected probes
under desired conditions. The selected conditions will
depend on the particular circumstances based on the par-
ticular criteria required (depending, for example, on the
G+C content, type of target nucleic acid, source of nucleic
acid, size of hybridization probe, etc.). Following washing
of the hybridized surface so as to remove nonspecifically
bound probe molecules, specific hybridization is detected, or
even quantitated, by means ofthe label.
11. Biological Functional Equivalents Modification and
changes may be madein the structure of the peptides of the
present invention and DNA segments which encode them
andstill obtain a functional molecule that encodesa protein
or peptide with desirable characteristics. The following is a
discussion based upon changing the amino acids of a protein
to create an equivalent, or even an improved, second-
generation molecule. The amino acid changes may be
achieved by changing the codons of the DNA sequence,
according to the following codon table:
 
TABLE1
Amino Acids Codons
Alanine Ala A GCA GCC GCG GCU
Cysteine Cys Cc UGC UGU
Aspartic acid Asp D GAC GAU
Glutamic acid Glu E GAA GAG
Phenylalanine Phe F UUC UUU
Glycine Gly G GGA GGC GGG GGU
Histidine His H CAC CAU
Isoleucine Tle I AUA AUC AUU
Lysine Lys K AAA AAG
Leucine Leu L UUA UUG CUA CUC CUG CUU
Methionine Met M AUG
Asparagine Asn N AAC AAU
Proline Pro P CCA CCC CCG CCU
Glutamine Gln Q CAA CAG
Arginine Arg R AGA AGG CGA CGC CGG CGU
Serine Ser S AGC AGU UCA UCC UCG UCU
Threonine Thr T ACA ACC ACG ACU
Valine Val V GUA GUC GUG GUU
Tryptophan Trp W UGG
Tyrosine Tyr Y UAC UAU
 
For example, certain amino acids may be substituted for
other amino acids in a protein structure without appreciable
loss of interactive binding capacity with structures such as,
for example, antigen-binding regions of antibodies or bind-
ing sites on substrate molecules. Since it is the interactive
capacity and nature of a protein that defines that protein’s
biological functional activity, certain amino acid sequence
substitutions can be made in a protein sequence, and, of
course, its underlying DNA coding sequence, and neverthe-
less obtain a protein with like properties. It is thus contem-
plated by the inventors that various changes may be madein
the peptide sequences of the disclosed compositions, or
corresponding DNA sequences which encode said peptides
without appreciable loss of their biologicalutility or activity.
In making such changes, the hydropathic index of amino
acids may be considered. The importance of the hydropathic
amino acid index in conferring interactive biologic function
on a protein is generally understood in the art (Kyte and
Doolittle, 1982, incorporate herein by reference). It is
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accepted that the relative hydropathic character of the amino
acid contributes to the secondary structure of the resultant
protein, which in turn defines the interaction of the protein
with other molecules, for example, enzymes, substrates,
receptors, DNA, antibodies, antigens, and the like.
Each amino acid has been assigned a hydropathic index
on the basis of their hydrophobicity and charge character-
istics (Kyte and Doolittle, 1982), these are: isoleucine
(+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8);
cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8);
glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan
(-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2);
glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); aspar-
agine (-3.5); lysine (-3.9); and arginine (-4.5).
It is known in the art that certain amino acids may be
substituted by other amino acids having a similar hydro-
pathic index or score andstill result in a protein with similar
biological activity, i.e., still obtain a biological functionally
equivalent protein. In making such changes,the substitution
of amino acids whose hydropathic indices are within +2 is
preferred, those which are within +1 are particularly
preferred, and those within +0.5 are even more particularly
preferred.
It is also understoodin theart that the substitution oflike
amino acids can be madeeffectively on the basis of hydro-
philicity. U.S. Pat. No. 4,554,101, incorporated herein by
reference, states that the greatest local average hydrophilic-
ity of a protein, as governed by the hydrophilicity of its
adjacent amino acids, correlates with a biological property
of the protein.
As detailed in U.S. Pat. No. 4,554,101, the following
hydrophilicity values have been assigned to amino acid
residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0+1);
glutamate (+3.0#1); serine (+0.3); asparagine (+0.2);
glutamine (+0.2); glycine (0); threonine (-0.4); proline
(-0.5+1); alanine (-0.5); histidine (-0.5); cysteine (-1.0);
methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine
(-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan
(-3.4).
It is understood that an amino acid can be substituted for
another having a similar hydrophilicity value andstill obtain
a biologically equivalent, and in particular, an immunologi-
cally equivalent protein. In such changes,the substitution of
amino acids whose hydrophilicity values are within +2 is
preferred, those which are within +1 are particularly
preferred, and those within +0.5 are even more particularly
preferred.
As outlined above, amino acid substitutions are generally
therefore based on the relative similarity of the amino acid
side-chain substituents, for example, their hydrophobicity,
hydrophilicity, charge, size, and the like. Exemplary substi-
tutions which take various of the foregoing characteristics
into consideration are well knownto those of skill in the art
and include: arginine and lysine; glutamate and aspartate;
serine and threonine; glutamine and asparagine; and valine,
leucine and isoleucine.
12. Site-Specific Mutagenesis
Site-specific mutagenesis is a technique useful in the
preparation of individual peptides,or biologically functional
equivalent proteins or peptides, through specific mutagen-
esis of the underlying DNA. The technique further provides
a ready ability to prepare and test sequence variants, for
example, incorporating one or more of the foregoing
considerations, by introducing one or more nucleotide
sequence changes into the DNA.Site-specific mutagenesis
allows the production of mutants through the use of specific
oligonucleotide sequences which encode the DNA sequence
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of the desired mutation, as well as a sufficient number of
adjacent nucleotides, to provide a primer sequence of suf-
ficient size and sequence complexity to form a stable duplex
on both sides of the deletion junction being traversed.
Typically, a primer of about 17 to 25 nucleotides in length
is preferred, with about 5 to 10 residues on both sides of the
junction of the sequence being altered.
In general, the technique of site-specific mutagenesis is
well knownin the art, as exemplified by various publica-
tions. As will be appreciated, the technique typically
employs a phage vector which exists in both a single
stranded and double stranded form. Typical vectors useful in
site-directed mutagenesis include vectors such as the M13
phage. These phage are readily commercially available and
their use is generally well knownto those skilled in theart.
Double stranded plasmids are also routinely employed in
site directed mutagenesis which eliminates the step of trans-
ferring the gene of interest from a plasmid to a phage.
In general, site-directed mutagenesis in accordance here-
with is performedbyfirst obtaining a single-stranded vector
or melting apart of two strands of a double stranded vector
which includes within its sequence a DNA sequence which
encodes the desired peptide. An oligonucleotide primer
bearing the desired mutated sequence is prepared, generally
synthetically. This primer is then annealed with the single-
stranded vector, and subjected to DNA polymerizing
enzymes such as E. coli polymerase I Klenow fragment, in
order to complete the synthesis of the mutation-bearing
strand. Thus, a heteroduplex is formed wherein one strand
encodes the original non-mutated sequence and the second
strand bears the desired mutation. This heteroduplex vector
is then used to transform appropriate cells, such as E. coli
cells, and clones are selected which include recombinant
vectors bearing the mutated sequence arrangement.
The preparation of sequence variants of the selected
peptide-encoding DNA segments using site-directed
mutagenesis is provided as a means of producing potentially
useful species and is not meant to be limiting as there are
other ways in which sequence variants of peptides and the
DNA sequences encoding them may be obtained. For
example, recombinant vectors encoding the desired peptide
sequence may be treated with mutagenic agents, such as
hydroxylamine, to obtain sequence variants.
13. Monoclonal Antibody Generation
Means for preparing and characterizing antibodies are
well known in the art (See, e.g., Antibodies: A Laboratory
Manual, Cold Spring Harbor Laboratory, 1988; incorporated
herein by reference).
The methods for generating monoclonal antibodies
(mAbs) generally begin along the samelines as those for
preparing polyclonal antibodies. Briefly, a polyclonal anti-
body is prepared by immunizing an animal with an immu-
nogenic composition in accordance with the present inven-
tion and collecting antisera from that immunized animal. A
wide range of animal species can be used for the production
of antisera. Typically the animal used for production of
anti-antisera is a rabbit, a mouse, a rat, a hamster, a guinea
pig or a goat. Because ofthe relatively large blood volume
of rabbits, a rabbit is a preferred choice for production of
polyclonal antibodies.
As is well knownin the art, a given composition may vary
in its immunogenicity. It is often necessary therefore to
boost the host immune system, as may be achieved by
coupling a peptide or polypeptide immunogento a carrier.
Exemplary and preferred carriers are keyhole limpet
hemocyanin (KLH) and bovine serum albumin (BSA).
Other albumins such as ovalbumin, mouse serum albumin or
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rabbit serum albumin canalso be usedas carriers. Meansfor
conjugating a polypeptide to a carrier protein are well
known in the art and include glutaraldehyde,
m-maleimidobencoyl-N-hydroxysuccinimideester, carbodi-
imide and bis-biazotized benzidine.
As is also well knownin the art, the immunogenicity of
a particular immunogen composition can be enhancedby the
use of non-specific stimulators of the immune response,
known as adjuvants. Exemplary and preferred adjuvants
include complete Freund’s adjuvant (a non-specific stimu-
lator of the immuneresponse containing killed Mycobacte-
rium tuberculosis), incomplete Freund’s adjuvants and alu-
minum hydroxide adjuvant.
The amount of immunogen composition used in the
production of polyclonal antibodies varies upon the nature
of the immunogenas well as the animal used for immuni-
zation. A variety of routes can be used to administer the
immunogen (subcutaneous, intramuscular, intradermal,
intravenous and intraperitoneal). The production of poly-
clonal antibodies may be monitored by sampling blood of
the immunized animal at various points following immuni-
zation. A second, booster, injection may also be given. The
process of boosting andtitering is repeated until a suitable
titer is achieved. Whena desired level of immunogenicity is
obtained, the immunized animal can be bled and the serum
isolated and stored, and/or the animal can be used to
generate mAbs.
mAbsmaybereadily prepared through use of well-known
techniques, such as those exemplified in U.S. Pat. No.
4,196,265, incorporated herein by reference. Typically, this
technique involves immunizing a suitable animal with a
selected immunogen composition,e.g., a purified orpartially
purified LTBP-3 protein, polypeptide or peptide. The immu-
nizing composition is administered in a mannereffective to
stimulate antibody producing cells. Rodents such as mice
and rats are preferred animals, however, the use of rabbit,
sheep frog cells is also possible. The use of rats may provide
certain advantages (Goding, 1986, pp. 60-61), but mice are
preferred, with the BALB/c mouse being most preferred as
this is most routinely used and generally gives a higher
percentage of stable fusions.
Following immunization, somatic cells with the potential
for producing antibodies, specifically B lymphocytes (B
cells), are selected for use in the mAb generating protocol.
These cells may be obtained from biopsied spleens, tonsils
or lymph nodes, or from a peripheral blood sample. Spleen
cells and peripheral blood cells are preferred, the former
because they are a rich source of antibody-producing cells
that are in the dividing plasmablast stage, and the latter
because peripheral blood is easily accessible. Often, a panel
of animals will have been immunized and the spleen of
animal with the highest antibody titer will be removed and
the spleen lymphocytes obtained by homogenizing the
spleen with a syringe. Typically, a spleen from an immu-
nized mouse contains approximately 5x10’ to 2x10° lym-
phocytes.
The antibody-producing B lymphocytes from the immu-
nized animal are then fused with cells of an immortal
myeloma cell, generally one of the same species as the
animal that was immunized. Myelomacell lines suited for
use in hybridoma-producing fusion procedures preferably
are non-antibody-producing, have high fusion efficiency,
and enzymedeficiencies that render then incapable of grow-
ing in certain selective media which support the growth of
only the desired fused cells (hybridomas).
Any one of a number of myelomacells may be used, as
are known to those of skill in the art (Goding, pp. 65-66,
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1986; Campbell, pp. 75-83, 1984). For example, where the
immunized animal is a mouse, one may use P3-X63/Ag8,
X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Agl4, FO, NSO/U,
MPC-11, MPC11-X45-GTG 1.7 and $194/5XX0 Bul; for
rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and
4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2
and UC729-6 are all useful in connection with human cell
fusions.
Onepreferred murine myelomacell is the NS-1 myeloma
cell line (also termed P3-NS-1-Ag4-1), which is readily
available from the NIGMS Human Genetic Mutant Cell
Repository by requesting cell line repository number
GM3573. Another mouse myeloma cell line that may be
used is the 8-azaguanine-resistant mouse murine myeloma
SP2/0 non-producer cell line.
Methods for generating hybrids of antibody-producing
spleen or lymph node cells and myeloma cells usually
comprise mixing somatic cells with myelomacells in a 2:1
ratio, though the ratio may vary from about 20:1 to about
1:1, respectively, in the presence of an agent or agents
(chemical or electrical) that promote the fusion of cell
membranes. Fusion methods using Sendai virus have been
described by Kohler and Milstein (1975; 1976), and those
using polyethylene glycol (PEG), such as 37% (v/v) PEG,
by Gefter et al., (1977). The use of electrically induced
fusion methods is also appropriate (Goding pp. 71-74,
1986).
Fusion procedures usually produce viable hybrids at low
frequencies, about 1x10~° to 1x10-°. However, this does not
pose a problem,as the viable, fused hybrids are differenti-
ated from the parental, unfused cells (particularly the
unfused myeloma cells that would normally continue to
divide indefinitely) by culturing in a selective medium. The
selective medium is generally one that contains an agent that
blocks the de novo synthesis of nucleotides in the tissue
culture media. Exemplary and preferred agents are
aminopterin, methotrexate, and azaserine. Aminopterin and
methotrexate block de novo synthesis of both purines and
pyrimidines, whereas azaserine blocks only purine synthe-
sis. Where aminopterin or methotrexate is used, the media is
supplemented with hypoxanthine and thymidine as a source
of nucleotides (HAT medium). Where azaserine is used, the
media is supplemented with hypoxanthine.
The preferred selection medium is HAT. Only cells
capable of operating nucleotide salvage pathwaysare able to
survive in HAT medium. The myelomacells are defective in
key enzymes of the salvage pathway, e.g., hypoxanthine
phosphoribosyl transferase (HPRT), and they cannot sur-
vive. The B-cells can operate this pathway, but they have a
limited life span in culture and generally die within about
two weeks. Therefore, the only cells that can survive in the
selective media are those hybrids formed from myelomaand
B-cells.
This culturing provides a population of hybridomas from
which specific hybridomasare selected. Typically, selection
of hybridomasis performed byculturing the cells by single-
clone dilution in microtiter plates, followed by testing the
individual clonal supernatants (after about two to three
weeks) for the desired reactivity. The assay should be
sensitive, simple and rapid, such as radioimmunoassays,
enzyme immunoassays, cytotoxicity assays, plaque assays,
dot immuno-binding assays, and the like.
The selected hybridomas would then be serially diluted
and cloned into individual antibody-producing cell lines,
which clones can then be propagated indefinitely to provide
mAbs. The cell lines may be exploited for mAb production
in two basic ways. A sample of the hybridoma can be
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injected (often into the peritoneal cavity) into a histocom-
patible animal of the type that was used to provide the
somatic and myeloma cells for the original fusion. The
injected animal develops tumors secreting the specific
monoclonal antibody produced by the fused cell hybrid. The
body fluids of the animal, such as serum orascites fluid, can
then be tapped to provide mAbs in high concentration. The
individual cell lines could also be cultured in vitro, where
the mAbsare naturally secreted into the culture medium
from which they can be readily obtained in high concentra-
tions. mAbs produced by either means may be further
purified, if desired, using filtration, centrifugation and vari-
ous chromatographic methods such as HPLC oraffinity
chromatography.
The following examples are included to demonstrate
preferred embodiments of the invention. It should be appre-
ciated by those of skill in the art that the techniques
disclosed in the examples which follow represent techniques
discovered by the inventorto function well in the practice of
the invention, and thus can be considered to constitute
preferred modesfor its practice. However, those of skill in
the art should, in light of the present disclosure, appreciate
that many changes can be madein the specific embodiments
which are disclosed andstill obtain a like or similar result
without departing from the spirit and scope of the invention.
EXAMPLE1
OLIGOPEPTIDE INDUCTION OF A
CYTOTOXIC T LYMPHOCYTE RESPONSE TO
HER-2/neu PROTO-ONCOGENEIN VITRO
A. MATERIALS AND METHODS
1. Peptides
HER-2 peptides were prepared by the Synthetic Antigen
Laboratory of M.D. Anderson Cancer Center (Houston,
Tex.) using Merrifield’s solid-phase system and a peptide
synthesizer (Ioannides et al., 1993). All reagents were of
high purity (>99%) and obtained from Millipore Corpora-
tion. Eluted peptides were transferred in aqueoussolution by
passing over Sephadex G-25 columns and lyophilized.
Crude synthetic peptides were separated by reverse-phase
HPLC.Identity and purity of the final materials were estab-
lished by amino acid analysis. Purification yielded single
peaks by analytical HPLC andthe purity of peptides used in
these studies was 297%.
2. Immunofluorescence
mAbs to CD3 (OKT3-FITC), CD4 (OKT4-FITC), and
CD8 (OKT8-FITC) were obtained from Ortho Diagnostic
(Ortho, Raitan, N.J.); mAb W6/32 (anti-HLA, -A, -B, -C)
was from Dako (Dako-Dakopatts, Denmark); and mAb
Leul 1a (anti CD16) was obtained from Beckton-Dickinson
(Mountain View, Calif.). mAb BB7.2 and MA2.1 (anti-
HLA-A2)-producing clones were from ATCC, mAb Ab2
against HER-2/neu was obtained from Oncogene Science
(Manhasset, N-Y.). Immunofluorescence studies were per-
formed as described (Ioannides et al., 1993).
3. Cells and Cell Lines Tumorlines and leukocytes of the
donors of ovarian malignant ascites were phenotyped for
HLA-A, B, and C antigens by the blood bank at M.D.
Anderson Cancer Center, Leukocytes of PBMC donors used
as responder cells (HLA-A, B, C) were typed at the Histo-
compatibility Laboratory of the Methodist Hospital
(Houston, Tex.). The HLA types of the donors are presented
in Table 2. Expression of HLA-A2 on ovarian tumors,
fibroblasts, and EBV-B cell lines (HLA-A2 transfectants)
was confirmed by immunofluorescence using culture super-
natant from mAb MA2.1 (Ioannides et al., 1993).
C1IR:A2, C1R:A1, and C1R:A3 cells express transfected
genomic clones of HLA-A2.1, HLA-Al, and HLA-A3.
10
15
20
25
30
35
40
45
50
55
60
65
30
These cells were obtained from Dr. William E. Biddison,
National Institute of Neurological Disorders, Bethesda, Md.
C1R (Class I reduced) is a mutant cell line that does not
express HLA-A2 (Bednarek et al., 1991; Gammon et al.,
1992). These cells were maintained in complete RPMI 1640
medium containing 100 ug/ml L-glutamine, 40 yxg/ml
gentamicin, and 10% fetal calf serum (FCS) (RPMI-FCS).
Ovarian tumors and lines of known HLA phenotype used in
these studies were: SKOV3 (HLA-A3, 28, B18, 35, Cw5),
OVA-1 (HLA-A1, 24, B8, 35, Cw4), OVA-14 (HLA-A2,30,
B14, 44, Cw2.8), OVA-16 (A2, 19 B8, 35), OVA-24 (HLA-
A2, 24, B8, 51, Cw2, 7), and (VA-31 (HLA-A11,-, B60, 62,
Cw3). Additional targets used in this study were the EBV-B
cell line XxCr (HLA-A2, -, B7, 8, Cw7) and the breast
carcinoma line SKBr3 (HLA-A11, -, B18, 40, Bw22).
SKBr3 overexpressing HER-2 was obtained from Dr. Mien
Chie-Hung, Department of Tumor Biology, M.D. Anderson
Cancer Center.
TABLE 2
 
HLA TYPING OF LYMPHOCYTE DONORS
 HLA type
No. Donor number A B Cc
1 30 2, 33 14, 35 w4
2. 41 1,2 8,— w7
3. 51 1,2 8,— w7
4, 46 2,2 18, 60 w3
5 86 2,2 18, 61 w3
6 14 32, — 41,51 N.D.?
7. 15 1, 32 8, 35 w4, w7
 
*Not determined.
Ovarian tumors were separated from TIL/TAL by cen-
trifugation over Ficoll-Hypaque gradients, as previously
described (Ioannides et al. 1991), and stored frozen in
aliquots in liquid nitrogen until used. Ovarian tumor lines
were maintained in culture in L-15 medium (Gibco, Life
Technologies, Grand Island, N.Y.) supplemented with 10%
FCS and 20 ug/ml gentamycin. Ovarian CTL-TAL lines
autologous with OVA-1, OVA-14, OVA-16, and OVA-31
have been generated as described from lymphocytes infil-
trating malignant ascites (TAL) by coculture of tumors with
TAL in RPMI-FCSin the presence of 25-50 U/ml of IL-2
(Cetus, Emeryville, Calif.) and 250 U/mlof tumornecrosis
factor-a (TNF-a) (Genentech, San Francisco, Calif.)
(Ioannides et al., 1991).
4. Transfection of Ovarian Tumor Line SKOV3 with
HLA-A2
The HLA-A2 expression vector RSV.5-neo containing
HLA-A2.1 full-length cDNA was provided by Drs. Richard
V. Turner and William E. Biddison. The RSV.5-neo expres-
sion vector is a derivative of RSV.3 (Jacobsonet al., 1989).
The SKOV3 cell line was cloned by stringent limiting
dilution (Ioannideset al., 1993), and individual clones were
transfected with the plasmid using the Lipofectin reagent
and procedure (Gibco-BRL, Gaithersburg, Md.) as
described by the manufacturer. Transfectants were selected
in culture with 800 ug/ml of G418 (Sigma Chemical Co., St.
Louis, Mo.). Surface expression of HLA-A2 was determined
by immunofluorescence with MA 2.1 mAb as described
(Ioannides et al., 1993). Several clones that expressed high
levels of HLA-A2 such as 2B6 (SKVO3.A2) were selected
for cytotoxicity studies.
5. Cytotoxicity Assays
Tumorcells and fibroblasts were labeled with 200 uCi of
“Cr (Na*?CrO,; Amersham,Arlington Heights,Il.) for 90
US 6,514,942 B1
31
min at 37° C. (Ioannidesetal., 1991). Lymphoblastoid cells
and HLA-A2 transfectants were labeled overnight in RPMI-
FCS, then washed three times and incubated with effector
cells in RPMI-FCSin an incubator with 5%. CO, (Bednarek
et al., 1991; Gammonetal., 1992). When peptide recogni-
32
later, cells were removed from cultures, washed, and
restimulated either with irradiated fresh autologous PBMC
or C1R:A2 cells pulsed with HER-2 additional days the
expanding cultures were restimulated with peptides follow-
 
5; : :tion was determined,targets were incubated with 25 uM of ing the procedures described above. Five to 6 daysafter the
peptides overnight during *'Cr labeling or with 10 uM second stimulation and 7 to 8 days after the third and
peptide for 2 h at 37° C. in RPMI-FCS then washed three subsequent stimulations, cultures were tested for cytotoxic
times before being incubated with effector cells. Separate activity against C1R:A2 cells pre-pulsed with HER-2 pep-
controls for spontaneous and total lysis were made for each to tides and unrelated control peptides containing HLA-A2
peptide-pulsed target (Ioannidesetal., 1991; Bednareketal., anchor motifs
1991; Gammonetal., 1992). After 4-5 h, 100 wl of super- , . . .
natant was collected and counted. To determine maximum Cultures that showedhigher lysis of targets pulsed with
lysis in 20-h assays, plates were left undisturbed in the HER-2 peptides than control peptides were maintained for
incubator and the supernatant wascollected after overnight further studies. These cultures were propagated and
incubation. For cold target inhibition studies, C1R:A2 cells 15 expanded by periodic cycles of restimulation with peptide-
were preincubated with ER ed contre peptides pulsed fresh autologous PBMCasantigen-presentingcells.
overnignt, then washed and admixed will Cr-labele After the fourth stimulation cells were gradually adapted totargets at 2:1 and 6:1 (cold:hot targets) ratios. Percentage . .lysi Iculated f, the fi la: 100x{(E-S)(T-S)] growth in RPMI-FCS by replacing 25% of the cultureysis was calculated from the formula: x , . . .. . . . medium every 3 days with RPMI-FCS over a period of 2whereE is experimental release, S is release in the absence 20 a in .of CTL, and Tis release in 2 M HCI. weeks. CD3 CD8*CD4 cells were isolated from bulk CTL
6. Generation of In Vitro HER-2 Peptide-Reactive CTL cultures by positive selection on anti-CD8 mAb-coated
CTL cultures reacting with HER-2 peptides were gener- Culture flasks (AIS Micro CELLector, Applied Immune
ated following procedures describedfor in vitro induction of Sciences, Menlo Park, Calif.) as described (Letessier etal.,influenza matrix and tum” peptide-specific CTL (Bednarek 25 1991). Isolated CD8 cells were restimulated with HER-2
et al., 1991; Gammonet al., 1992; Alexander et al., 1991) peptide-pulsed PBMC, either autologous or in some
with several modifications. In brief, PBMC from HLA-A2* instances allogeneic that matched only HLA-A2 with the
and HLA-A2~ donors were separated by Ficoll-Hypaque™ responding cells.
TABLE 3
SEQUENCES OF PEPTIDES
Sequence
Peptide? 1 2 3 4 5 6 7 8 9 10 11 12 13 14 SEQID NO:
1.C43 R F R ELV S EF S&S RM AR 652. C85 E LV S EF S$ RM 73. C84 ELV S EF S$ RY 64.C44 R F R- EL I LT EF S RM AR 665.D132. Mucii6-1 S L A D P A HG V 676.D125 Muc-1:8-17 G L T S A P DT R-Y¥ 68
 
*Peptides 1-4 are analogs of HER-2:968-981 (C43 and C44) and 971-979 (C85 and C84).
The substitution VS—II in C44 is found in the equivalent sequence of the epidermal growth
factor receptor. D132 is an analog of the Muc-1 core peptide where L(P2) and D(P4) sub-
stitute for Thr and Pro, respectively, to create a P2 anchor and a hydrophilic residue at P4,
respectively. In the D125 peptide, also an analog of the muc-1 core peptide, L(P2) and
V(P10) also substitute for Val and Pro, respectively. Substituted amino acids are in bold and
underlined.
gradient centrifugation. PBMC (5-10x10°) were washed, 5, B. RESULTS
resuspended in a final volume of 100-250 wl in PBS, and
incubated with the stimulating peptide for 90 min at 37° C.
The final concentration of the stimulating peptide ranged
between 5 and 50x10~° M. Afterwards, cells were irradiated
(4000 rad), washed, and plated in wells of 24-well plates
(Costar, Cambridge, Mass.) in 2.0 ml at a final concentration
of 0.5-1.0x10° cells/ml. As responding cells, autologous
PBMCwere added at a final concentration of 1.0-1.5x10°/
ml. Sequences of HER-2 peptide analogs used for stimula-
tion or specificity determination are presented in Table 3.
Cultures were initiated in RPMI 1640 medium containing
100 ug/ml L-glutamine, 40 wg/ml gentamycin, and 5%
heat-inactivated and sterile-filtered human AB plasma
(RPMI-HS). After 3 days, 5 U of IL-2 (Cetus) was added in
each well. One unit of IL-2 (Cetus) equals 6 IU of IL-2
(Ioannides et al., 1991). After 2 additional days one-third of
the medium from each well was replaced with an equal
volume of RPMI-HScontaining 15 U/ml of IL-2. Four days
60
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1. Generation of In Vitro HER-2 Peptide Reacting CTLs
To define conditions for in vitro CTL induction by stimu-
lation with HER-2 peptides of PBMC from healthy
volunteers, two synthetic peptides were used for priming:
(1) C43 (HER-2:968-981)=RFRELVSEFSRMAR (SEQ ID
NO:31), which contains as HLA-A2 anchors Leu(972) at P2
and Met(979) at P9, includes two Rothbard epitope motifs
ELVS and RMAR and most of the amphiphilic area
968-984; and (2) C84 (HER-2:971-979(Val)=ELVSEFSRV
(SEQ ID NO:6) where Met(P9) has been substituted by Val
because Val is the dominant anchor residue at P9 and
although it does not contact the TCR (Maldenet al., 1993),
it stabilizes the HLA-A2-HER-2 peptide complex. Leu and
Metwerealso found in CTL epitopes at P9, as indicated by
sequence information (Parkeret al., 1992). These peptides
were selected because of our previous observations that
tumor reacting CTL-TAL isolated from lymphocytes infil-
trating ovarian malignant ascites can recognize synthetic
US 6,514,942 B1
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peptides derived from the highly amphiphilic area HER-
2:968-984 on HLA-A2*targets (Ioannideset al., 1993). All
cultures were initiated in RPMI-HSto avoid induction of
T-cells reactive with determinants on FCS proteins. In
contrast, cytotoxicity assays were performed in RPMI-FCS
to minimize interferences from recognition by CTL of
humanproteins (Wolfel et al., 1993).
The ability of PBMCcultures to recognize peptides used
for priming was determined by measuring the lysis of
peptide-pulsed C1R:A2 cells. Three out of five individual
cultures tested lysed C1R:A2 targets pulsed with C43, C84,
or both. Results with two representative donors (No. 41 and
No. 51) are shown in FIG. 1. It should be mentioned that
these two donors were siblings and had identical HLA
phenotype. A common feature of C43- and C84-induced
cultures wasthat they showed minimallysis of C1R:A2 cells
in 4-h cytotoxicity assays but significant differences were
observed between lysis of peptide pulsed and control
C1R:A2 targets in 20-h assays at 2-3 weeks after stimula-
tion. When cytotoxicity was determined early (1 week after
stimulation), in certain instances, they showed high back-
groundlysis. Interestingly, all cultures stimulated with the
C84 peptide showed similar levels of lysis of either C43-or
C84-pulsed targets in 20-h cytotoxicity assays (FIG. 1A,
FIG. 1B, FIG. 1C, FIG. 2A, and FIG. 2B).
HER-2 peptide-stimulated PBMCcultures tend to lose
specificity over time and that the numbers of CD8*cells tend
to decrease, due to overgrowth of CD4* cells. CD8* cells
were isolated from bulk CTL cultures from donor 41 by
positive selection on anti-CD8 mAb-coated plates. The
resulting cells were 100% CD3*, 97% CD8*, and 1% CD4*.
Separated CD8* cells were propagated in culture by
repeated stimulations with C43 and C84 peptide-pulsed
PBMCand expanded in medium containing 15-25 U/mlof
IL-2 for more than 6 months. The 41.CD8* CTL line
recognized both C43 and C84 peptides and at a much lesser
extent, control D125 and D132 peptides. These peptides
contain HLA-A2 anchors introduced by us but differ in
sequence form HER-2 peptides (Table 3). The absence of
HLA-A2 anchorsin the natural sequence of D125 and D132
suggests that they are not presented to corresponding CTL in
humans. The sequences of D125 and D132 were chosen
from Muc-l core sequence (Gendleret al., 1988). When C43
and C84 peptides were preincubated with C1R:A1 cells
(HLA-A1 transfectants which expressed only HLA-A1),
41.CD8* CTLfailed to elicit a higher lysis of peptide pulsed
than of control targets. Similar results were observed with
HLA-A3 transfectants (FIG. 2A and FIG. 2B). These results
suggested that 41.CD8* CTL line is peptide Ag specific.
Similar results were obtained with PBMC from donor 30
stimulated with C43/C84 peptides. HLA-A2* transfectants
did not cross-present C43/C85/C84 to HLA-A2- CTL from
donors 14 and 15 (Table 3) induced with the same peptides.
This may suggest that recognition of C43/C84 is HLA-A2
restricted. C43/C85/C84 lack anchor residues for HLA-
A1:E(P3), P(P4) and Y(P9); HLA-B8:K(P3), R(P5) and
L(P9) (Dibrino et al., 1994), as well as for HLA-B35:Pro
(P2) and Tyr(P9) (Hill et al., 1992).
2. HER-2 Peptide-induced CD8* Cells can Lyse Ovarian
Tumors Overexpressing HER-2 Proto-oncogene
In vitro peptide-induced CTL cultures can recognize
HER-2 peptides used as immunogen. The major question
with respect to the specificity of in vitro-induced CTL is
whether they can specifically lyse targets endogenously
expressing the antigen of interest. To address this question,
the ability of HER-2 peptide-stimulated CTL to lyse ovarian
tumors overexpressing HER-2 protein was investigated. The
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ability of 41.CD8* CTL line to lyse an ovarian tumor
(OVA-16) overexpressing HER-2 was tested using
NkK-sensitive targets as lysability controls. OVA-16 tumor
shared HLA-A2 with donor 41 effectors (Table 2). The
ability of 41.CD8* effectors to lyse OVA-16 was determined
at 4 and 20 h. The results are shown in FIG. 3A and FIG.3B.
As expected from the results presented in FIG. 1A, FIG. 1B,
FIG. 1C, FIG. 2A and FIG.2B,lysis of OVA-16 by 41.CD8*
effectors in 4-h assays was low, although higher than K562.
In 20-h cytotoxicity assays, lysis of OVA-16 was signifi-
cantly higher than K562 cells.
To determine whether susceptibility of ovarian tumors to
lysis correlates with levels of HER-2 protein expression on
tumor, the ability of the 41.CD8* CTL line to lyse two
HLA-2*fresh isolated ovarian tumors OVA-16 and OVA-14
wastested. The results are presented in FIG. 3C. Both shared
only HLA-A2 with the donor 41, but they differed at the
levels of expression of HER-2. Immunofluorescence stain-
ing with the anti-HER-2-specific mAb showed 77.5% HER-
2* cells with a mean fluorescence intensity (MFI) of 28.67
for OVA-16 and 17.4% HER-2* cells with a MFIof 6.2 for
OVA-14. They were designated as HER-2”2" and HER-2’°”
respectively. The control HLA-Atarget, ovarian tumorline
SKOV3 (99% HER-2*) was also designated as HER-2’"2".
The 41.CD8* line showed significantly higher lysis of
HER-2”8” than HER-2’°" targets, suggesting that lysis of
HER-2 expressing ovarian tumors may be dependent on Ag
density. Lysis of the OVA-14 tumor was similar to that of
control XxCr and C1R:A2 cells (HLA-A2*, HER-2°) and
SKBr3 (HLA-A2-, HER-2”2"). The SKOV3 tumor (HLA-
A2-, HLA-A3*, HER-2”"8”) was lysed at levels comparable
with control lines, suggesting that HER-2 recognition
requires presentation by HLA-A2, because SKOV3.A2 tar-
gets were recognized. Both OVA-14 and OVA-16 expressed
comparable levels of HLA-A2 antigens on the surface as
determined by immunofluorescence with MA2.1 mAb
(92.1% HLA-A2 positive cells and 49.0 mean fluorescence
for OVA-14 and 85.3% HLA-A2 positive cells and 42.0
mean fluorescence for OVA-16, respectively). In separate
studies, OVA-16, OVA-14, and SKOV3 tumors were effi-
ciently lysed by LAK cells, suggesting that there were no
major differences in their lysability by cytolytic effectors.
It is unlikely that tumor killing by 41.CD8* CTLreflects
LAK type activity. LAK cells lyse K562 with higher effi-
ciency than they lyse human tumors (Grimm et al., 1982).
Also, both C1R:A2 and SkOV3.A2 were transfected with
the same HLA-A2 plasmid expression vector. Therefore,
lysis of SKOV3.A2 but not of C1R:A2 suggests that
41.CD8* CTL are not only HLA-A2 reactive but also Ag
reactive. In separate studies, LAK cells lysed effectively
both C1R:A2 and T2 cells. This lysis was not affected by
C43/C84 or mutated peptides based on this sequence. These
results show that HER-2 peptide-induced CD8* cells from
human PBMCcanrecognize targets endogenously express-
ing HER-2 protein.
To confirm that the 41.CD8* CTLline recognizes epitopes
on HER-2”2" tumors contained on peptides used for
stimulation, cold target inhibition studies were performed. In
an attempt to inhibit lysis of the OVA-16 tumor by 41.CD8*
CTLwith either C43- or C85-(the wild-type HER-2 peptide
971-979) pulsed C1IR:A2 cells were used with C1R:A2 cells
alone or pulsed with the D125 peptide as controls. The
results are shown in FIG. 4A and FIG. 4B. Inhibition of
OVA-16 lysis by the 41.CD8* line was observed in both 4-
and 20-h assays. C43- and C85-pulsed C1R:A2 cells but not
specificity controls, C1R:A2 cells alone or pulsed with the
D125 peptide,inhibited the lysis of the OVA-16 tumor. As
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expected, levels of lysis were lower in 4-h versus 2-h assays.
Increasing the cold:hot ratio to 6:1 did not significantly
increase the inhibitory effects of the HER-2 peptide-pulsed
C1R:A2. That highly specific, but incomplete, inhibition
wasobserved here and in other human CTL systems (Jerome
et al., 1993) reflect low Ag (peptide) density on targets use
for inhibition or an increase in background nonspecific lysis
as observed in FIG. 3C.
These peptides were recognized by autologous tumor
reactive CTL-TAI, suggesting the presence on the tumor of
similar or cross-reactive CTL epitopes (Ioannides et al.,
1993). To address whether these peptides interfere with
tumor lysis by autologous tumor reactive CTL-TAL in
HLA-A2> systems, the lysis of OVA-1, HER-2”2" (HLA-
Al, 24, B8, 35, Cw4) and OVA-31, HER-2’"8” was deter-
mined by pre-pulsing with either C43 or as a control, C44
peptide (VS—-I]). Target lysis by CTL-1 was: OVA-1 (68%),
K562 (18%), OVA-1 plus C43 (37%), and OVA-1 plus C44
(51%). C43 significantly inhibited by 45% lysis of OVA-1
by CTL-1, while less inhibition (25%) was observed with
C44. However, C43 and C44 had no effect on lysis of
OVA-31 by CTL-31. This suggested that these peptides can
bind certain MHCClass I heavy chains other than HLA-A2
and can interfere with lysis of certain HLA-A2™ tumors by
autologous CTLs.
Therefore CD8* CTL lines can be induced in vitro with
HER-2 peptide analogs and lyse ovarian tumors overex-
pressing HER-2.It is also likely that a T-cell epitope with a
sequence similar or cross-reacting with peptide analogs from
the area HER-2:968—981is associated with HLA-A2 on the
tumorcell surface.
C. DISCUSSION
Evidence has been presented showing that human PBMC
from healthy volunteers can be primed in vitro with HER-2
peptide analogs to develop lymphocyte cultures with
Ag-specific CTL activity. A CD8* CTLline developed from
bulk cultures recognized not only peptides used as immu-
nogen but also ovarian tumors endogenously expressing
HER-2. Peptide-induced CD8* CTL lysed targets endog-
enously expressing HER-2 but not K562 cells, an ovarian
tumor expressing low levels of HER-2. Furthermore, based
on the ability of C1R:A2 cells pulsed with C43, C85, or C84
to inhibit HER-2”2" tumor lysis compared with the inability
of C1R:A2 cells alone or pulsed with D125 to mediate the
same inhibition, the findings demonstrate that HER-2
peptide-induced CD8* CTL recognizes similar or cross-
reactive epitopes on tumors expressing HER-2. At similar
levels of HLA-A2 expression efficiency of tumor lysis was
dependent on the levels of HER-2 expression.
The weak lysis observed in 4-hr assays does notreflect
“slow” lysis. Slow lysis rarely achieves target lysis above
50% at E:T ratios of 60:1 in 20- to 24-hr assays (Ratner and
Clark, 1993). CTL showedlevels of lysis in the range of
60-80% at 10:1 or even 5:1 E:T ratios. One possibility to be
considered is that the frequency of HER-2 reactive clones in
peptide-induced CTLs is relatively low and they diluted
among non-cytotoxic cells. The 41.DD8* line secreted
TNEF-A when cocultured overnight with C1R:A2 cells in the
presence, but not in the absence, of HER-2 peptides. TNF-A
secretion was inhibited by HLA-A2 specific MA2.1 mAb,
suggesting that peptide recognition associated with HLA-A2
is needed for lymphokine secretion. With respect to the
efficiency of these peptides for target sensitization for maxi-
mum lysis this was observed when targets were preincu-
bated with 5 uM peptide for 1 hr or cultured with 25 uM
peptide overnight. The amount of peptide bound on HLA-
A2* molecules cannot be estimated, however, by comparing
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with other reports on human CTLassays performed in the
presence of peptide in solution, these CTLs needed 2-3x
10?-fold more peptide for similar levels of target
recognition, but in 20-hr assays (Gammon et al., 1992;
Schmidtet al., 1991; Kos and Mullbacher, 1992; Stauss et
al., 1992; Anderson etal., 1992). This peptide concentration
is significantly less than the 107-fold difference in peptide
concentration needed for efficient Ag recognition reported
for murine CTL induced in vivo and in vitro by peptides
(Schild et al., 1991).
It may be possible that if HLA-A2 acts as a restriction
elementfor specific HER-2 peptides, TCR with highaffinity
for these natural peptides may be eliminated during thymic
selection, leaving only TCR with low affinity (Bownesset
al., 1993). The only conservative substitution introduced to
strengthen the P9 anchor (Met—>Val) had no inhibitory
effects in peptide-stimulating ability or CTL specificity.
TCR contacts mainly residue in the sequence P4—P7, while
P2 and P9 are buried in the HLA-A2 binding pockets
(Madden et al., 1993). Of interest, the 14mer peptide C43
had similar sensitizing ability for lysis of targets as the
shorter peptide C84. Although it may be possible that
activity in C43 is associated with the presence of contami-
nating peptides at levels lower than the ability of detection,
several other possibilities need to be taken in consideration:
proteolytic degradation as extracellular processing occurs
and the longer peptides are better substrates than shorter
than peptides for proteolysis (Sherman et al., 1992). This
may also suggest a role for the group RFR and/or the
carboxy-terminal R in Ag processing before HLA-A2 bind-
ing.
Since targets were always pulsed with the same concen-
trations of peptides, the kinetics of target recognition may
also reflect different effects of factors involved in in vitro
priming of T-cells with Ag. It has been previously shown
that by increasing both responder cell and Ag (peptide)
density, murine Ag-specific CTL can be induced in vitro.
These CTL recognized targets which endogenously
expressed the Ag of interest (Winter et al., 1991).
The experience with in vitro induction of human CTLs by
peptide is limited. Recent reports have shown that
Ag-specific CTLs can be induced in vitro using peptide
analogs of EBV nuclear antigens (EBNA) (Schmidtet al.,
1992), influenza matrix (Bednarek et al., 1991; Gammonet
al., 1992), or Plasmodium falciparum pre-erythrocytic stage
antigens (Hill et al., 1992). Given the frequency of EBV and
influenza infections it is possible that they represented, at
least in some instances, secondary CTL responses of in
vivo-primed T-cells. Based on molecular mimicry between
self and foreign proteins at the three and tetrapeptide levels
(Ohno, 1991), it is not unlikely that naturally processed
T-cell epitopes from self-proteins may be cross-reactive
(Anderson et al., 1992).
Since HER-2 is a self-antigen, HER-2 reactive T-cells
may be primed in vivo and non-deletional mechanisms of
tolerance in the periphery may render HER-2-primed T-cells
anergic or suppressed. However, a recent report demon-
strated that Ag-reactive T-cells transferred in Ag-reactive
T-cells transferred in Ag tolerant transgenic mice can be
recovered, suggesting that tolerance induction in the periph-
ery may not affect primed T-cells and that the lack of
auto-reactivity may be because of the low levels of antigen
expressed on normal cells (Hu et al., 1993). The HER-2
proto-oncogene productis expressed at low levels in normal
cells of origin. Results suggest that in vivo priming to
HER-2 epitopes is possible when HER-2 is expressed at
100- to 200-fold higher than normallevels (loannideset al.,
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1993). In contrast with viral infections which essentially
turn off the host protein synthesis to favor the expression of
virally coded polypeptides, overexpression of HER-2 does
not generally inhibit the tumor’s protein synthesis. Thus,
additional antigens are expected to compete with HER-2 for
HLA-A2 binding and presentation to TCR.
PBMCfrom 5 of 11 healthy HLA-A2* volunteers tested
showed CTL responses to HER-2 peptides used for priming,
and CTLs and tumorclones have been developedto identify
HER-2 epitopes recognized by tumorreactive CTLs.
EXAMPLE 2
SEQUENCE MOTIFS OF HUMAN HER-2
PROTO-ONCOGENE IMPORTANT FOR
PEPTIDE BINDING TO HLA-A2
A. MATERIALS AND METHODS
1. Peptides
HER-2 peptides were synthesized as described in
Example 1. The purity of peptides used in these studies was
297%.
2. Immunofluorescence
mAbs to CD3 (OKT3-FITC), CD4 (OKT4-FITC) and
CD8 (OKT8-FITC) were obtained from Ortho Diagnostic
(Ortho, Raritan, N.J.), mAb W6/32 (anti-HLA,-A, -B, -C)
from Dako (Dako-Dakopatts, Denmark); HLA-A2 reacting
mAb BB7.2 and MA2.1 from ATCC. Immunofluorescence
studies were performed as described in Example 1.
3. HLA-typing
Leukocytes of the PBMC donors used as respondercells
were typed by the Blood Bank at M.D. Anderson Cancer
Center. The HLA-types were as follows: donor 20: HLA-A
2, 11, B35, 51, Cw7, donor 25: HLA-A 2, 3, B44, 60; donor
30: HLA-A2, 33 B14, 35, Cw4. Expression of HLA-A2 on
HLA-A2 transfectants was confirmed by immunofluores-
cence using culture supernatant from mAb MA2.1
(Joannides et al., 1993).
4. Cytotoxicity Assays
Target cells were labeled with °*Cr (Na°?CrO,;
Amersham, Arlington Heights, Ill.) for 90 min at 37° C.
(loannides et al., 1991; Ioannides et al., 1991), or overnight
in RPMI medium, containing 10% FCS, 100 yxg/ml
L-glutamine and 40 ug/ml gentamycin (RPMI-FCS), then
washed and incubated with the effector cells in complete
RPMI-FCS in an incubator with 5% CO,. Targets were
incubated either with 25 uM of peptide overnight during
labeling, or with 10 uM peptide for 2 h at 37° C. in
RPMI-FCS,then washed three times before being incubated
with effector cells. Separate controls for spontaneous and
total lysis of targets were made for each peptide pulsed
target (Ioannideset al., 1993; Fisk et al., 1994; Gammonet
al., 1992). After 4-5 h of incubation 100 yl of supernatant
were collected and counted. Percent lysis was calculated
from the formula: 100x[(E-S)(T-S)], were E=experimental
release, S=release in the absence of CTL, T=release in 2 M
HCl.
5. Target Cells and Cell Lines
The human lymphoblastoid cell lines C1R and T2 have
been previously described (Gammonet al., 1992; Bednarek
et al., 1991; Salter and Creswell, 1986; Anderson et al.,
1993). C1R (Class I reduced) is a mutantcell line that does
not express HLA-A2, C1R:A2 cells express transfected
genomic clones of HLA-A2.1. These cells were obtained
from Dr. William E. Biddison (National Institute of Neuro-
logical Disorders, Bethesda, Md.). T2 (transport deletion
mutant) cells were obtained from Dr. Peter Creswell (Yale
University School of Medicine, New Haven, Conn.).
C1R:A2 cells were maintained in RPMI-FCS.T2 cells were
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maintained in Iscove’s Modified Dulbecco Medium
(IMDM)containing 5% Fetal Calf Serum (IMDM-FCS).
6. Generation of In Vitro HER-2 Peptide-reactive CTL
CTL cultures were generated following the procedures
described for in vitro induction of influenza matrix and tum
peptide specific CTL (Gammonetal., 1992; Bednareket al.,
1991; Salter and Creswell, 1986) with several modifications.
In brief, PBMC from HLA-A2* donors were separated by
Ficoll-Hypaque™ gradient centrifugation. 5-10x10° PBMC
were resuspended in a final volume of 100-250 ul in PBS
and incubated with the stimulating peptide at a final con-
centration between 5—50x10-° M for 90 min at 37° C.
Afterwards, cells were irradiated (4000 rad), washed, and
plated in wells of 24 well plates (Costar, Cambridge, Mass.)
in 2.0 mlat a final concentration of 0.5—1.0x10° cells/ml. As
responders, autologous PBMC were added at a final con-
centration of 1.0-1.5x10°/ml.
Cultures were initiated in RPMI 1640 medium containing
100 “g/ml L-glutamine, 40 “g/ml gentamycin and 5% heat-
inactivated and sterile filtered human AB plasma (RPMI-
HS). The use of human serum during stimulation and culture
and of FCS during CTL assays was intended to avoid
induction of FCS peptide reactive CTLs. After three days, 5
U of IL-2 (Cetus) equals 6 IU of IL-2 (loannides et al.,
1991). Two dayslater, one third of the medium was replaced
with an equal volume of RPMI-HScontaining 15 U/ml of
IL-2. Four dayslater, cells were restimulated with irradiated
fresh autologous PBMCpulsed with the same peptides.
Three days later, 5 U of IL-2 (Cetus) was addedto each well.
The expanding cultures were subjected to a second round of
restimulation as described above. Six daysafter the first and
second stimulations and seven to eight days after the third
stimulation, cultures were tested for cytotoxic activity
against C1R:A2 cells pulsed with either stimulating peptides
or unrelated control peptides. Control cultures were estab-
lished without HER-2 peptides, containing the same number
of autologous stimulators and responders PBMC.
7. Proliferation Assays
Fresh PBMCfrom healthy volunteers isolated by Ficoll-
Hypaque™ were distributed into 96-well round-bottomed
plates (Falcon, Becton-Dickinson) at 2x10°/well in RPMI-
FCS. Peptides were added at 50 ug/ml. The studies were
performedat least twice using PBMCfrom the same donor,
in quadruplicate. After 5 days, for the last 16 h in culture,
wells were pulsed with 1 #Ci of [°H]-thymidine @H-Tdr)
and counted. Proliferation was determined as °H-Tdrincor-
poration and c.p.m. determined in the samples of PBMC
cultured with peptides and were divided by c.p.m. deter-
mined samecultures in the absence of peptides, to determine
the stimulation index (S.I.).
B. RESULTS
1. Selection of Candidate Antigenic Peptides from HER-2
Peptides Predicted by Algorithmic Methods
Sequence analysis for the presence of potentially
amphiphilic areas revealed a small number (<20) of poten-
tial sites capable of forming long amphiphilic a-helices over
3-4 turns (12 residues) in the 1255 residue sequence of
HER-2 (Ioannides et al., 1993). A number of shorter
sequences have also been identified. Most of these
sequences contained Rothbard’s epitope motifs (Rothbard
and Taylor, 1988). Since the focus was peptides presented by
HLA-A2, these regions as well as the entire HER-2
sequence were searched for areas containing the predicted,
as well as the alternatively reported, HLA-A2 anchors: i.e.
L/M/1/V (P2) and V/L/M/I (P9) (Parmiani, 1993; Bednarek
et al., 1991; Parkeret al., 1992). Several areas were found
to meet all three criteria of selection. These areas are as
follows:
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(a) HER-2: 968-984, which not only forms a perfect
amphiphilic helix but also contains two Rothbard’s
epitope motifs and a nonapeptide with predicted HLA-
A2 anchors. This area has been previously found to be
recognized by tumor reactive CTL (Ioannides et al.,
1993).
(b) The area HER-2:41-56 contains L(43), L(49) and the
group VV(55-56). This corresponds to two overlap-
ping potentially HLA-A2 binding peptides: an octapep-
tide HER-2:42-49 followed by a nonapeptide HER-
2:48-56. The presence of HL and VV groups renders
these peptides highly hydrophobic, and consequently
they have low solubility in PBS or culture medium.
With respect to the sequence HER-2:48—56,the corre-
sponding synthetic peptide (D113) had low solubility in
PBS. DMSO upto 50% wasused for rapid solubiliza-
tion. The analogs D114=HER-2:47-56(48H-L) and
D115=HER-2:48-56(48H-G) were designed in an
attempt to improve solubility and increase the ability of
exogenously supplied peptides to bind to HLA-A2. To
overcome these problems at least in part, peptides
D96=HER-2:4-54 and D97=HER-2:42-51 were
synthesized, which, although longer than the minimum
HLA-A2 binding peptide, are water-soluble.
(c) The area HER-2:391-411 contains two potentially
HLA-A2 binding nonapeptides: HER-2:391-399
(PLQPEQLOQV) (SEQ ID NO:12) and HER-2:402-410
(TLEEITGYL) (SEQ ID NO:13). An octapeptide HER-
2:396-403 with HLA-A2 anchors at P2 and
P8:QLOVFETL (SEQ ID NO:14) is nested in the
sequence and overlaps with the carboxy- and amino
terminal regions of the HER-2:391-399 and 402-410.
Two other areas containing decapeptides: HER-
2:344-353=GLGMEHLREV (SEQ ID NO:15) and HER-
2:1089-1098=DLGMGAAKGL (SEQ ID NO:16) both
include predicted HLS-A2 anchors but not overlapping or
continuous epitopes. Several other areas also show potential
amphiphilic sites and include Rothbard’s epitope motifs.
While these areas do not include HLA-A2 anchor motifs,
they may, however, include anchors for other HLA-types.
2. Peptides Identified by the Presence of HLA-A2
Anchors
In addition to the sites identified by the overlap of
potentially amphiphilic sites and Rothbard’s epitope motifs,
a numberof peptides can be identified in the sequence of
HER-2 by the presence of HLS-A2 anchorsat positions 2
and 9. A large numberofsites (>35) containing nonapeptides
with: dominant, strong or weak P2 and P9 anchors predicted
or reported for HLA-A2 (Falket al., 1991) were found in the
HER-2 sequence. The sequences of most of these peptides
are presented in Table 4. Additional nonapeptides are found
in the Leu and Val rich transmembrane domain (655-675).
In addition to nonamers, a large number of octa- and
decamers were found in the HER-2 sequence containing
L/I/V/M as HLA-A2 anchors. These sequences are not
included in Table 4 except in a few cases where octa- and
decamersare part of epitope clusters. In addition to clustered
potential HLA-A2 binding peptides from the signal
(Ioannides et al., 1992; Ioannides et al., 1993; Parmiani,
1993; Slamon et al., 1989; Fisk et al., 1994; Falk et al., 1991;
Rothbard and Taylor, 1988; DeLisi and Berzofsky, 1985;
Stauss et al., 1992) and transmembrane (655-675) areas,
putative HLA-A2 binding peptides are clustered either as
continuous or overlapping peptides as follows: 42-91 (two
8- and three 9-mers), 141-179 (three 9-mers), 391-419
(three 9-mers), continued with 423-474 (six 9-mers),
781-807 (three 9-mers and one 10-mer), 828-859 (one
8-mer and four 9-mers).
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In certain areas, the last two carboxyterminal residues of
a putative HLA-A2 binding peptide overlap with the first
two aminoterminal residues of the next peptide because P2
and P9 anchors are the same or similar (L/V). Most of the
peptides include Rothbard’s epitope motifs. However most
of the nonapeptides either do not derive from long
amphiphilic areas, or are highly hydrophobic according to
their sequence; when their sequence is viewed on axial
projection (Edmundson’s wheel) (Kaiser and Kezdy, 1984)
the majority of the peptides (28/38) show limited segrega-
tion of hydrophilic and hydrophobic residues.
Crystallographic analysis of the LSA-A2 peptide complex
reveals an additional binding pocket in HLA-A2 accommo-
dating a hydrophobic residue in position 6 and the likelihood
that residues in positions 4 and 8 are hydrophilic and
oriented upwards (towards TDR) (Saperet al., 1991; Mad-
den et al., 1993). None of the nonapeptides of sequences
shown in the Table 4 contains all the additional strong
anchorsin the positions 4, 6, and 8 identified by Rammensee
and collaborators (Falk et al., 1991). Howeverat least 3/17
nonamerscontain one additional strong HLA-A2 anchor and
11/18 nonamerscontainsat least two additional weak HLA-
A2 anchors (Table 5). For peptide selection the following
groups were considered equivalent: L and I at P2, R and K
at Pa, P4, P5 and P8, L and M at P9,either because of
TABLE 4
 
HER-2/NEU PEPTIDES CONTAINING P2 AND
P9 HLA-A2 ANCHORS?
From Amino Acid To Amino Acid
Peptide No. Position # Position #
1 5 13
2 42 49
3 48 56
4 76 84
5 84 91
6 141 149
7 160 168
8 171 179
9 369 377
10 391 399
11 402 410
12 411 419
13 423 431
14 435 443
15 442 450
16 447 455
17 457 465
18 466 474
19 596 604
20 603 611
21 627 635
22 650 658
23 689 697
24 747 755
25 781 790
26 789 797
27 793 801
28 799 801
29 828 836
30 835 842
31 838 846
32 845 853
33 851 859
34 883 891
35 904 912
36 971 979
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TABLE 4-continued
 
HER-2/NEU PEPTIDES CONTAINING P2 AND
P9 HLA-A2 ANCHORS* 5
From Amino Acid To Amino Acid
Peptide No. Position # Position #
37 986 994
38 1172 1180
10
*Selection of anchors was made from the cDNA sequence of human HER-
2/neu (Yamamoto et al., 1986). To accommodate HER-2 peptides that may
bind HLA-A2 with low affinity both I and V were accepted at position 2.
Based on reported epitopes, I can be tolerated at P2. V binds with much
loweraffinity to HLA-A2. CTL epitopes containing V at P2 have not been
reported yet. CTL epitopes containing M at P9 have been reported (Parker 45
et al., 1992). Although M is tolerated at P2 only octa- and deca-peptides
were found containing M (P2) in the HER-2 sequence, and they are not
included in this table. For the sequences of each of the motifs, see Fisk et
al., 1994b.
structural similarities, or because they have been reported to
be part of CTL epitopes (Parker et al., 1992). 20
Sequence analysis of HLA-A2 bound peptides shows an
alternation of hydrophobic and hydrophilic residues. P2 and
P3 are generally made of hydrophobic residues, P4 of
hydrophilic residues, while the charge and hydropathy of
residues in P5—P9 alternate, following in general the pattern: 25
P5 (variable/neutral)}—P6 (hydrophobic)—P7 (variable)—
P8 (hydrophilic)—P9 (always hydrophobic) (Falk et al.,
1991). Although the peptide is bound to HLA in an extended
conformation stabilized with hydrogen bonds, the alterna-
tion between hydrophobic and hydrophilic residues is in 39
general agreement with Rothbard’s epitope motifs and with
hypotheses that certain T-cell epitopes are derived from
amphiphilic sites.
Examination of the physicochemical properties of HER-2
peptides may assist in predicting which of the peptides 35
shownin Table 4 will bind HLA-A2. However this would
not address whether these self-peptides are capable of acti-
vating T-cells. To gain insight into these questions, specific
areas were targeted: 41-56, 392-411, and 968-984. Each
area contains a nonapeptide: 48-56 (D113), 402-410 (D119) 49
and 971-979 (C85). All share Leu as P2 anchor. Peptide
43-56 contains the dominant P9 anchor Val, while 402-410
contains Leu and 971-979 contains Met which are expected
42
to be weak anchors. All share a hydrophilic residue at P4:
D97 (Q), D119 (E) and C85 (S). Differences are evident in
the residues in the other positions, where only C85 has a
strong P8 anchor (R). The sequences of peptides from these
regions are shown in the Table 4.
3. Effects of HER-2 Synthetic Analogs on Conformational
Epitopes on HLA-A2
To determine whether these peptides and longer analogs
affect HLA-A2 conformation as an indication of HLA-A2
binding, the effects of HER-2 peptides on the reactivity of
conformationally dependent mAb MA2.1 and BB.7.2 were
examined with HLA-A2 of T2 cells. The humancell line T2
has a defect affecting endogenous peptide loading of MHC
class I molecules. As a consequence,cell surface expression
of HLA-A2 is lower (30-40%) than in normal LBL lines
transfected with HLA-A2 (e.g., C1R) but the reactivity of
MA2.1 and BB.7.2 mAbis increased when certain HLA-A2
binding peptides are added to the culture medium (Anderson
et al., 1993). Although most human MHCclass I molecules
cannot be induced at the low temperatures used for their
murine counterparts because of fundamental structural dif-
ferences between human and mouseclass I (Andersonetal.,
1993), the fact that they express few endogenous (mainly
signal) peptides (Zweerink et al., 1993) increases the sen-
sitivity of detection of peptide-HLA-A2 interaction.
The results of immunofluorescence studies are presented
in FIG. 5A, FIG. 5B, FIG. 5C, and FIG. 5D. The nonapep-
tide D113 induced a significant increase in FL1. As
expected, its analogs D114 and D115 increased FL1 even
further (FIG. 5A). However since they have shown low
solubility, the study was repeated with peptides dissolved in
DMSO. The nonapeptide D113 induced a significant
decrease in the reactivity of MA2.1 mAb with HLA-A2.
Both D114 and D115 were unable to increase reactivity of
MA2.1 with HLA-A2. In contrast, D97 which has identical
P1i-—2 anchors with D113 but nests an octapeptide, D96
which covers the entire area 41-54 with the exception of the
VV group (P8-9) of D113 and decapeptide D99=
DLGMGAAKGL (HER-2:1089-1098) (SEQ ID NO:5)
showeda slight increase in FL1 of T2 cells in comparison
with control peptides (D98 and D100) or in the absence of
peptide.
TABLE 5
 
HER-2 PEPTIDES CONTAINING ADDITIONAL
HLA-A2 ANCHORS TO P2 AND P9 
Peptide Sequence No. of Anchors SEQ ID
No. Position 1 2 3 4 5 6 7 8 9 Strong Weak NO:
1 48-56 H L YY QGc¢C QV Vv 2 2 17
2 76-84 D I Q Ev QGyY Vv 3 1 20
3 141-149 Q LR S LT ETIL 1 4 21
4 171-179 D I F H K NN QL 1 3 22
5 369-377 K I F GS L A FL 1 6 11
6 391-399 P LQ P EQLoQ qv 2 1 12
7 402-410 T L E EIT GY iL 2 3 13
8 411-419 Y I S AW POD S L 1 4 23
9 457-465 S L R EL GS GL 2 3 24
10 650-658 P LT S I I S A V 2 2 25
11 689-697 R L LQ E T EL V 2 2 26
12 747-155 K I P VA IK VL 1 4 27
13 789-797 c LTS TVQL iv 3 0 10
14 828-836 Q I A K GM SS Y L 2 3 28
15 851-859 vVLvVkK S PN HV 3 1 8
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TABLE5-continued
HER-2 PEPTIDES CONTAINING ADDITIONAL
HLA-A2 ANCHORS TO P2 AND P9
Peptide Sequence No. of Anchors SEQ ID
No. Position 1 2 3 4 5 6 7 8 9 Strong Weak NO:
16 971-979 E LV S E F S RM 2 1 7
17 1172-1180 T LS P GK N G V 2 2 29
TABLE 6
SEQUENCES OF HER-2 PEPTIDES USED IN THIS STUDY
SEQ ID
Peptide Position Sequence NO:
HER-2
Peptides:
D97 42-51 H L DM LRH L Y¥ Q 30
D96 41-54 T H L DM LR AHL YY Q GC Q 31
D113 48-56 H LY QGcCeQVvV Vv 17
D114 47-56 R LLY QGc¢CQ Vv Vv 18
D115 48-56 G LY QGC QV Vv 19
D98 N Q E V T AWD GTQ R 32
D119 402-410 T L E EIT GY iL 13
D120 397-410 L QV F E T L E E I T GY L 33
D121 392-411 LQ P E QL QV F E T L EE SIT G YL Y 34
D122 396-406 QL Qwv F ET LEE! 35
D95 392-404 L Q P E QL QV F E TLE 36
C85 971-979 E LV S E F S RM 7
C86 971-981 E LV S E F S RM A R 37
C43 968-981 R F R E L V S E F S§ RM AR 38
C44 968-981 R F R E L I IT E F S&S RM AR 39
B69 972-984 L V S E F S§& RM A R D P Q 40
C61 968-977 R F R E L V S E F § 41
D169 964-972 EC R P R F RED 42
D170 968-984 R F R E L V S 43
D99 1089-1098 DLGM GA AK GL 16
D100 1086-1098 F DG DLGM GAAK GL 45
FBPPeptides:
E37 25-33 R I A W AR T E L 46
E38 112-120 N L GPW IQeQ Vv 47
E39 191-199 E I W TH S T K V 48
E40 247-255 S LA LM LLUWL 49
E41 245-253 L LS L ALM UL 50
 
*Underlined residues represent mutations from the natural sequence of HER-
>D169 wasselected to contain HLA-B8 anchors, shown underlined.
Of peptides from the area 392-410, the analog D119
corresponding to a nonapeptide with dominant P2 and weak
P9 anchor showed a significant increase in FL1 over control
T2 cells preincubated without peptide. Interestingly, amino-
terminal elongation of the peptide (D120) and elongation
followed by truncation (D122) increased the FL1 only
slightly over the base level. Similarly, a peptide (D121)
containing the entire area failed to significantly affect the
FL1, suggesting that it is probably not processed by external
proteases to shorter fragments of correct length.
The model nonapeptide C85 (=HER-2:971-979) from the
third area failed to significantly increase FL1 of T2 cells
reacting with MA2.1. C85 contains a dominant P2, a strong
P8 and weak P9 anchor. This was also true for longer
analogs B69 and C43. To address the question whetherthis
reflects the weakness of the P9, and P6 anchors analogs
C84(M-V), C83(RM--KV) and C81(F—V, RM-KV)
were synthesized. Peptide C84 induceda significant increase
in FL1 that was comparable with D119 (FIG. 5C), suggest-
ing that the presence of a strong anchorat P9 in this peptide
is important for induction of a MA2.1 conformational
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epitope on T2. C83 did not increase further the FL1,
suggesting that the substitution R~K maynotbecritical for
reactivity of MA2.1 with HLA-A2. Of note, C81 signifi-
cantly increased the FL1, suggesting that the presence of V
at P6 is important for induction of MA2.1 conformational
epitopes. Since the previous data suggest that C85 may
interact with HLA-A2,the reactivity of BB7.2 mAb with T2
cells preincubated with the same peptides was examined.
The results show that C85 induces an increase in FL1 of
cells stained with BB.7.2 (FIG. 5D). The analogs C84 and
C81 induced an even higher increase in FL1 of cells reacted
with BB.7.2.
To clarify whether (L/I (P2) and V/L (P9) as critical
elements for induction of MA2.1 conformational epitopes is
restricted to HER-2, a control study analyzed the effect on
FL1 of T2 cells stained with MA2.1 of five nonapeptide
analogs from the sequence of folate binding protein (FBP)
which is also overexpressed in ovarian cancer. The results
are presented in FIG.6. Offive peptides, one (E37)failed to
affect MA2.1 epitope expression, three showed a moderate
increase similar with C84 regardless that either Leu or Val
US 6,514,942 B1
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were present P9, and only one showed a very high increase
in FL1. This peptide (E38) has a different P2 (L vs I) from
E39 which showed only a moderate increase in FL1 and
included I(P6). Two other peptides (E40-E41) containing the
groups ALM and MLLat P5-P7failed to induce an increase
in FL1. Theseresults indicate that in addition to the presence
of predicted dominant P2 and P9 anchors, induction of
conformational MA2.1 epitopes on HLA-A2 also depends
on the peptide sequence at P3-P8. It is likely that the
presence of certain residues affects the reactivity of MA2.1
mAb with HLA-A2. Therefore MA2.1 epitope expression
alone does not necessarily reflect the affinity of peptide
binding to MA2.1.
4. Stimulation of Peptide Reactive CTL In Vitro
HER-2 peptides (Table 6) were tested for their ability to
stimulate HLA-A2* PBMCto proliferate in vitro. PBMC
from healthy donors were incubated with HER-2 peptides
from the groups:41—56, 392-410 and 968-984 for 5 days.
With few exceptions, significant cell proliferation was not
observed in all 4 PBMC samples from individual donors of
different HLA-types including HLA-A2. (S.I. ranged
between 0.8-1.5) suggesting that these short peptides were
not mitogenic. The exception to these observations was
Donor 20.8.1. for D95 was 6.4, for D121 was4.3, but for the
nonamer D119 wasonly 1.1. Similarly, the S.I. for the longer
peptide D96 (41-54) was2.8 butfor the shorter peptide D97
wasonly 1.5. These differences werestatistically significant.
Proliferation of PBMC stimulated with peptides in the
presence of IL-2 failed to clearly distinguish between pep-
tides that induced lymphocyte proliferation and those that
did not, because of the overall increase in the levels of
proliferation of both control and peptide stimulated samples.
To address the question of whetherin vitro stimulation of
PBMC with HER-2 peptides followed by culture in the
presence of IL-2 leads to T-cell phenotype change, the %
CD3, CD4, and CD8 expression on the surface of HER-2
peptide-stimulated PBMC were determined. Theresults of a
typical study are shown in FIG. 7A, FIG. 7B and FIG. 7C.
Nine daysafter the first stimulation with either peptide D97
(a decamer containing a nested octapeptide), D121 (a
20-mer containing nested an octapeptide and a nonapeptide)
and C85 (nonapeptide) and expansion in IL-2,all cultures
showed a significant increase in CD8* cells and a decrease
in CD4* cells was observed associated with overall cell
expansion and growth. This trend continued in all cultures
and 10-15 days after a third stimulation, with the same
peptide in all cultures, CD4* cells constituted the dominant
(>80%) cell population.
5. Lytic Activity and Specificity of HER-2 Peptide-
Stimulated PBMC
To elucidate the ability of HER-2 peptides to induce CTLs
in vitro, the ability of HLA-A2* PBMC cultured in the
presence of HER-2 peptides and IL-2 to recognize peptides
used as stimulators was determined. HER-2 peptides with
different sequences were used as specificity controls.
C1R:A2 cells were used as targets because they express only
HLA-A2.A first group of peptides selected as stimulators
were from the area HER-2:41-56 as follows: D96 and D97
containing the octapeptide:42—49, and D113 and D114 cor-
responding to the overlapping peptides 48-56 and 47-56.
Stimulation and restimulation with irradiated autologous
PBMCpulsed with peptide showed mixedresults. In certain
cases, higher peptide recognition was determined, in others
lack of peptide specificity was observed. In most cultures,
after the second stimulation with HER-2 peptides, CD4*
cells became the dominant population, and they expressed
either LAK type lytic activity or failed to recognize the Ag
used for stimulation.
10
15
20
25
30
35
40
45
50
55
60
65
46
The results of a typical study that used as targets three
HER-2 peptides and as effectors PBMC from donor 20
stimulated either once with D97 or cultured in the same
conditions in the absence of HER-2 peptide (as control) are
shown in FIG. 8A, FIG. 8B, and FIG. 8C. Control cultures
showed low levels of similar lysis of all targets. In contrast,
cultures stimulated with D97 showedat 6:1 E/T ratio some-
whathigher lysis of targets pulsed with the peptides used for
stimulation, than of control peptides D98 (no HLA-A2
anchors) and D99 but the background lysis wasrelatively
high. Similarly when PBMC from the same donor were
stimulated with D96 which includes the area HER-2:42-51,
higher lysis of targets pulsed with D97 than D96 was
observed (FIG. 9A, FIG. 9B, and FIG. 9C). The same
cultures showed lower lysis of targets pulsed either with
control D95 peptide (not used for stimulation), or control
C1R:A2 cells, or the NK sensitive targets K562 cells. D97
stimulated PBMCfrom the donor 30 showedhigherlysis of
targets pulsed with D97 than with the overlapping 48—56 and
control D119 nonapeptides. The results are shown in FIG.
9A, FIG.9B, and FIG. 9C.In 2/3, donors peptides D96/D97
induced in vitro CTLs can preferentially recognize the
peptide used as stimulator. This suggests that a potential
epitope capable of stimulating T-cells in vitro is nested in the
area 42-51.
Peptide D113 and its mutated analog D114 induced a CTL
response which apparently lacked Ag specificity (FIG. 10A
and FIG. 10B). Although in 2/3 HLA-A2* donors,at certain
E:T ratios peptide induced CTL showed higher recognition
of targets pulsed with D113 than of control D119 peptide,
the differences were minimal. These peptide-induced CTL
were designated as non-specific. D113, D114 and D115
showed higher increase in reactivity of MA2.1 mAb with
HLA-A2 than D96/D97. Howeverthey inducedless specific
CTL than D96/D97. The reasons for these differences are
unknown, however the results should be interpreted with
caution because ofthe difficulties in solubilizing D113 and
its analogs.
The peptide D121 (HER-22:392-411) induced a CTL
response that lacked Ag specificity (FIG. 11A). However,
D121 stimulated PBMC from donor 20 showed somewhat
higher lysis of targets pulsed with the nonapeptide D119
than D121, but this response was short-lived. PBMC from
two other donors (25 and 30) stimulated with D121 and
D119, were used as effectors to determine the specificity of
D119 recognition of every peptide. Similar results were
obtained with peptide stimulated PBMC from donor 30.
Peptide recognition was also determined in 20 h cytotoxicity
assays. No major differences in recognition of targets pulsed
with peptides used as stimulator versus control peptides
were observed. Similarly D119 was found to increase the
reactivity of MA2.1 mAb with HLA-A2 on T2 cells but
failed to induce peptide specific CTLs (FIG. 11B and FIG.
11C).
EXAMPLE3
Synthesis of Novel Universal Immunodominant
Peptide Epitopes
A large numberof nonapeptides (synthetic analogs) have
been constructed, and it has been determined which ones are
recognized by CTLs associated with and lysing ovarian
tumors. Of more than 15 peptides tested for recognition by
three HLA-A2+ CTL lines, the following peptides have been
recognized more often. Based on the levels of lysis induced
they were designated as high: C85 (2/3); E90 (2/3), E75
(2/3) E71 (2/3), E89 (2/3); and moderate E77 (2/3).
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The sequences of these peptides are as follows:
C85 = HER-2:971-979 - ELVSEFSRM_ (SEQ ID NO:E89 = HER-2:851-859 -V LVKS PNHV_ (SEQ ID NOE71 = HER-2:798-806 -QLMPYGCLUL_ (SEQ ID NO:
E90 = HER-2:788-796 -C LTSTVQLV_ (SEQ ID NO:E75 = HER-2:370-378 -KIFGSLAFUL_ (SEQ ID NO:E77 = HER-2:391-399 -PLQPEQLQV_ (SEQ ID NO:
The ability of these peptides to sensitize targets for lysis
by tumorassociated CTLs(relative to positive control C85)
is shown in Table 7.
These sequences, being immunodominant, can provide
universal HER-2 targets and antigens for CTLs in the
HLA-A2 system expressed by over 45% of North American
population.
Since HER-2is a self-antigen, during thymic selection, a
number of T-cells carrying receptors with high affinity for
the HLA-peptide complex are silenced either by elimination
ro tolerization. A pre-condition for induction of a high
affinity TCR-(MHC+peptide) interactions, is a stable
(MHC+peptide) complex. Therefore T-cells reacting with
peptides that bind HLA with low affinity and have weak
stabilizing effect, are not likely to be eliminated in vivo but
they can become CTL targets. However, stabilization of
HLA-Class I binding by exogenously added peptide is
dependent on introduction of dominant anchors in positions
P2 and P9 which are not recognized by TCR.In addition to
patenting this concept we found that replacement of Met
(P9) stabilize HLA-A2 expression on an indicator line T2
used for these types of studies.
TABLE 7
 
RECOGNITION OF HER-2 PEPTIDES BY OVARIAN
TUMOR ASSOCIATED CYTOTOXIC T LYMPHOCYTES
 
CTL-24 % of C85*
High
cgs? 1.000
E90 0.885
E75 0.850
Moderate
E77 0.759
E89 0.734
E71 0.625
Negative
D113 0.095
D99 0.050
D97 -0.025
CTL-34 % of C85
High
C85 1.000
E90 1.149
E89 1.149
Moderate
E71 0.600
E77 0.300
CTL-16
High
E75 >10.00°
 
“The levels of targets lysis by CTL in the presence of each HER-2 peptide
are shown as % of positive control (C85 peptide) recognition by CTL.
E75 wasthe only peptide significantly recognized by this CTL line.
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C85=ELVSEFSRM (SEQ ID NO:7) is the natural non-
apeptide recognized by CTL. Peptides C84=ELVSEFSRV,
(SEQ ID NO:6) and C83=ELVSEFSKV (SEQ ID NO:5)are
analogs with strengthened P9 and P8. C84 also can specifi-
cally inhibit tumor lysis by peptide induced CTL.
Furthermore, Leu (P2) is a dominant anchor, but E (P1) may
be electrostatically rejected by residues that form the MHC
class I binding pocket. Thus replacement of EG (P1)
(neutral) or EK (P1,positive charge) are also expected to
stabilize the interaction, while the residues being buried in
the pocket, are expected not to affect CTL recognition.
The analogs with sequences C91=GLVSEFSRYV, (SEQ ID
NO:4) and C92=KLVSEFSRV (SEQ ID NO:3) are also
compositions of the present invention. In addition, substi-
tutions at P4 (SK) and P6 (FV)affect residues that are
expected to interact with TCR. The analog C81=ELVSEVS
KV (SEQ ID NO:2) stabilized HLA-A2 more than C84,
while C82: ELVKEVSKYV (SEQ ID NO:1) although binds
HLA-AZ2 is no longer recognized by C84 reactive CTL. Both
C81 and C82 can form the core for antagonists of HER-2
reactive CTLs (to control and stop CTL reactions), and as
such represent the first “universal” antagonists reported for
stimulating CTLs.
Peptide D113, HLYQGCQVV(SEQ ID NO:17), is the
natural nonapeptide HER-2:42-51. D113 stabilizes HLA-
A2 on indicator T2 cells. The novel synthetic peptide analog,
D114, RLLYQGCQVV (SEQ ID NO:18), shows little
improvement on stabilization of HLA-A2, but the novel
peptide, D115, GLYQGCQVV (SEQ ID NO:19), shows
significantly higher improvement which confirmed the pre-
dictions above.
EXAMPLE4
Peptide Formulations
Peptides containing the epitope motifs described herein
are contemplated for use in therapeutics to provide universal
HER-2 targets and antigens for CTLs in the HLA-A2 system
expressed by over 45% of the North American population.
The development of therapeutics based on these novel
sequences provides induction of tumor reactive immune
cells in vivo through the formulation of synthetic cancer
vaccines, as well as induction of tumor-reactive T-cells in
vitro through either peptide-mediated (e.g., lipopeptide) or
cell-mediated (e.g., EBV-B lines using either autologous or
HLA-A2 transfectants where the gene for the peptide of
interest is introduced, and the peptide is expressed associ-
ated with HLA-A2 on the surface). The use of these novel
peptides as components of vaccines to prevent, or lessen the
chance of cancer progression is also contemplated.
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The peptides contemplated for use, being smaller than
other compositions, such as envelope proteins, will have
improved bioavailability and half lives. If desired, stability
examinations may be performed on the peptides, including,
€.g., pre-incubation in human serum and plasma; treatment
with various proteases; and also temperature- and
pH-stability analyses. If found to be necessary, the stability
of the synthetic peptides may be enhanced by any one of a
variety of methods such as, for example, employing
D-amino acids in place of L-amino acids for peptide syn-
thesis; using blocking groups like t-boc and the like; or
encapsulating the peptides within liposomes. The bio-
availability of select mixtures of peptides may also be
determined by injecting radio-labeled peptides into experi-
mental animals, such as mice and/or Rhesus monkeys, and
subsequently analyzing their tissue distribution.
If stability enhancement was desired, it is contemplated
that the use of dextrorotary amino acids (D-amino acids)
would be advantageous as this would result in even longer
bioavailability due to the inability of proteases to attack
these types of structures. The peptides of the present inven-
tion may also be further stabilized, for example, by the
addition of groups to the N- or C-termini, such as by
acylation or amination. If desired, the peptides could even be
in the form of lipid-tailed peptides, formulated into
surfactant-like micelles, or other peptide multimers. The
preparation of peptide multimers and surfactant-like
micelles is described in detail in U.S. Ser. No. 07/945,865,
incorporated herein by reference. The compositions of the
present invention are contemplated to be particularly advan-
tageous for use in economical and safe anti-tumor/anti-
cancer therapeutics, and specific therapeutic formulations
may be tested in experimental animal models, such as mice,
rats, rabbits, guinea pigs, cats, goats, Rhesus monkeys,
chimpanzees, and the like, in order to determine more
precisely the dosage forms required.
In addition to the peptidyl compoundsdescribed herein,
the inventors also contemplate that other sterically similar
compounds may be formulated to mimic the key portions of
the peptide structure and that such compounds mayalso be
used in the same manner as the peptides of the invention.
This may be achieved by the techniques of modelling and
chemical design known to those of skill in the art. For
example, esterification and other alkylations may be
employed to modify the terminus of a peptide to mimic a
particular terminal motif structure. It will be understood that
all such sterically similar constructs fall within the scope of
the present invention.
Therapeutic or pharmacological compositions of the
present invention will generally comprise an effective
amount of a CTL-stimulating peptide or peptides, dissolved
or dispersed in a pharmaceutically acceptable medium. The
phrase “pharmaceutically acceptable” refers to molecular
entities and compositions that do not produce an allergic,
toxic, or otherwise adverse reaction when administered to a
human. Pharmaceutically acceptable media or carriers
include any and all solvents, dispersion media, coatings,
antibacterial and antifungal agents, isotonic and absorption
delaying agents and the like. The use of such media and
agents for pharmaceutical active substances is well known in
the art. Except insofar as any conventional media or agentis
incompatible with the active ingredient, its use in the thera-
peutic compositions is contemplated.
Supplementary active ingredients can also be incorpo-
rated into the therapeutic compositionsof the present inven-
tion. For example, the stimulatory peptides may also be
combined with peptides including cytotoxic T-cell- or
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T-helper-cell-inducing epitopes (as disclosed in U.S. Ser.
No. 07/945,865; incorporated herein by reference) to create
peptide cocktails for immunization and treatment.
The preparation of pharmaceutical or pharmacological
compositions containing a CTL-stimulating peptide or
peptides, including dextrorotatory peptides, as active ingre-
dients will be knownto those of skill in theart in light of the
present disclosure. Typically, such compositions may be
prepared as injectables, either as liquid solutions or suspen-
sions; solid forms suitable for solution in, or suspension in,
liquid prior to injection; as tablets or other solids for oral
administration; as time release capsules; or in any other form
currently used, including cremes, lotions, mouthwashes,
inhalents and thelike.
Solutions of the active compoundsas free base or phar-
macologically acceptable salts can be prepared in water
suitably mixed with a surfactant, such as hydroxypropylcel-
lulose. Dispersions can also be prepared in glycerol, liquid
polyethylene glycols, and mixtures thereof and in oils.
Under ordinary conditions of storage and use, these prepa-
rations contain a preservative to prevent the growth of
microorganisms.
Sterile solutions suitable for intravenous administration
are preferred in certain embodiments and are contemplated
to be particularly effective in stimulating CTLs and/or
producing an immuneresponse in an animal. The pharma-
ceutical forms suitable for injectable use include sterile
aqueoussolutions or dispersions and sterile powders for the
extemporaneouspreparationofsterile injectable solutions or
dispersions.In all cases the form mustbesterile and must be
fluid to the extent that easy syringability exists. It must be
stable under the conditions of manufacture and storage and
must be preserved against the contaminating action of
microorganisms, such as bacteria and fungi.
A peptide or peptides can be formulated into a composi-
tion in a neutral or salt form. Pharmaceutically acceptable
salts, include the acid addition salts (formed with the free
amino groups of the peptide) and which are formed with
inorganic acids such as, e.g., hydrochloric or phosphoric
acids, or such organic acids as acetic, oxalic, tartaric,
mandelic, and the like. Salts formed with the free carboxyl
groups can also be derived from inorganic bases such as, for
example, sodium, potassium, ammonium,calcium,or ferric
hydroxides, and such organic bases as isopropylamine,
trimethylamine, histidine, procaine, and the like.
The carrier can also be a solvent or dispersion medium
containing, e.g., water, ethanol, polyol (for example,
glycerol, propylene glycol, and liquid polyethylene glycol,
and the like), suitable mixtures thereof, and vegetable oils.
The properfluidity can be maintained byinteralia the use of
a coating, such as lecithin, by the maintenance of the
required particle size in the case of dispersion and by the use
of surfactants. The prevention of the action of microorgan-
isms can be brought inter alia by various antibacterial ad
antifungal agents, for example, parabens, chlorobutanol,
phenol, sorbic acid, thimerosal, and the like. In many cases,
it will be preferable to include isotonic agents, e.g., sugars
or sodium chloride. Prolonged absorption of the injectable
compositions can be brought about by the use in the com-
positions of agents delaying absorption, for example, alu-
minum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating
the active compounds in the required amountin the appro-
priate solvent with various of the other ingredients enumer-
ated above, as required, followed by filtered sterilization.
Generally, dispersions are prepared by incorporating the
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various sterilized active ingredients into a sterile vehicle
which contains the basic dispersion medium and the
required other ingredients from those enumerated above.In
the case of sterile powders for the preparation of sterile
injectable solutions, the preferred methods of preparation
are vacuum-drying and freeze-drying techniques which
yield a powderof the active ingredient plus any additional
desired ingredient from a previously sterile-filtered solution
thereof.
The preparation of more- or highly-concentrated solutions
for intramuscular injection is also contemplated. This is
envisioned to have particular utility in facilitating the treat-
mentof needle stick injuries to animals or even humans.In
this regard, the use of DMSOassolventis preferred as this
will result in extremely rapid penetration, delivering high
concentrations of the active peptide, peptides or agents to a
small area.
The use of sterile formulations, such as saline-based
washes, by veterinarians, technicians, surgeons, physicians
or health care workers to cleanse a particular area in the
operating field may also be particularly useful. Therapeutic
formulations in accordance with the present invention may
also be reconstituted in the form of mouthwashes, including
the peptides alone, or in conjunction with antifungal
reagents. Inhalant forms are also envisioned, which again,
may contain active peptides or agents alone, or in conjunc-
tion with other agents, such as, e.g., pentamidine. The
therapeutic formulations of the invention may also be pre-
pared in forms suitable for topical administration, such as in
cremesandlotions.
Buffered ophthalmic solutions also fall within the scope
of the invention, and may be created in accordance with
conventional pharmaceutical practice, see for example
“Remington’s Pharmaceutical Sciences” 15th Edition, pages
1488 to 1501 (Mack Publishing Co., Easton, Pa.). Suitable
ophthalmic preparations will generally contain a novel
dipeptide, peptide or agent as disclosed herein in a concen-
tration from about 0.01 to about 1% by weight, and prefer-
ably from about 0.05 to about 0.5%, in a pharmaceutically
acceptable solution, suspension or ointment. The ophthalmic
preparation will preferably be in the form of a sterile
buffered solution containing, if desired, additional
ingredients, for example preservatives, buffers, tonicity
agents, antioxidants and stabilizers, nonionic wetting or
clarifying agents, viscosity-increasing agents andthe like.
Suitable preservatives for use in such a solution include
benzalkonium chloride, benzethonium chloride,
chlorobutanol, thimerosal and the like. Suitable buffers
include boric acid, sodium and potassium bicarbonate,
sodium and potassium borates, sodium and potassium
carbonate, sodium acetate, sodium biphosphate and the like,
in amounts sufficient to maintain the pH at between about
pH 6 and pH 8,and preferably, between about pH 7 and pH
7.5. Suitable tonicity agents are dextran 40, dextran 70,
dextrose, glycerin, potassium chloride, propylene glycol,
sodium chloride, and the like, such that the sodium chloride
equivalent of the ophthalmic solution is in the range
0.9+0.2%. Suitable antioxidants and stabilizers include
sodium bisulfite, sodium metabisulfite, sodium thiosulfate,
thiourea and the like. Suitable wetting and clarifying agents
include polysorbate 80, polysorbate 20, poloxamer 282 and
tyloxapol. Suitable viscosity-increasing agents include dex-
tran 40, dextran 70, gelatin, glycerin, hydroxyethylcellulose,
hydroxmethylpropylcellulose, lanolin, methylcellulose,
petrolatum, polyethylene glycol, polyvinyl alcohol,
polyvinylpyrrolidone, carboxymethylcellulose and the like.
Upon formulation, therapeutics will be administered in a
manner compatible with the dosage formulation, and in such
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amount as is pharmacologically effective. The formulations
are easily administered in a variety of dosage forms, such as
the type of injectable solutions described above, but drug
release capsules and the like can also be employed. As used
herein, “pharmacologically effective amount” means an
amount of composition is used that contains an amountof a
peptide or peptides sufficient to significantly stimulate a
CTL or generate an immune response in an animal.
In this context, the quantity of peptide(s) and volume of
composition to be administered depends on the host animal
to be treated, such as, the capacity of the host animal’s
immune system to produce an immune response. Precise
amounts of active peptide required to be administered
depend on the judgmentof the practitioner and are peculiar
to each individual.
A minimal volume of a composition required to disperse
the peptide is typically utilized. Suitable regimes for admin-
istration are also variable, but would be typified by initially
administering the compound and monitoring the results and
then giving further controlled doses at further intervals. For
example, for parenteral administration, a suitably buffered,
and if necessary, isotonic aqueous solution would be pre-
pared and used for intravenous, intramuscular, subcutaneous
or even intraperitoneal administration. One dosage could be
dissolved in 1 mlof isotonic NaCl solution and either added
to 1000 ml of hypodermoclysis fluid or injected at the
proposed site of infusion, (see for example, “Remington’s
Pharmaceutical Sciences” 15th Edition, pages 1035-1038
and 1570-1580).
In certain embodiments, active compounds may be
administered orally. This is contemplated for agents that are
generally resistant, or have been renderedresistant, to pro-
teolysis by digestive enzymes. Such compounds are con-
templated to include chemically designed or modified
agents; dextrorotatory peptides; and peptide and liposomal
formulations in timed-release capsules to avoid peptidase,
protease and/or lipase degradation.
Oral formulations may include compounds in combina-
tion with an inert diluent or an edible carrier which may be
assimilated; those enclosed in hard- or soft-shell gelatin
capsules; those compressed into tablets; or those incorpo-
rated directly with the food of the diet. For oral therapeutic
administration, the active compounds may be incorporated
with excipients and used in the form of ingestible tablets,
buccal tables, troches, capsules, elixirs, suspensions, syrups,
wafers, and the like. Such compositions and preparations
should generally contain at least 0.1% of active compound.
The percentage of the compositions and preparations may, of
course, be varied and may conveniently be between about 2
to about 60% of the weightof the unit. The amountof active
compounds in such therapeutically useful compositions is
such that a suitable dosage will be obtained.
Tablets, troches, pills, capsules and the like may also
contain the following: a binder, as gum tragacanth, acacia,
corn starch, or gelatin; excipients, such as dicalctum phos-
phate; a disintegrating agent, such as corn starch, potato
starch, alginic acid and the like; a lubricant, such as mag-
nesium stearate; and a sweetening agent, such as sucrose,
lactose or saccharin may be addedor aflavoring agent, such
as peppermint, oil of wintergreen, or cherry flavoring. When
the dosage unit form is a capsule, it may contain, in addition
to materials of the above type, a liquid carrier. Various other
materials may be present as coatings or to otherwise modify
the physical form of the dosage unit. For instance, tablets,
pills, or capsules may be coated with shellac, sugar or both.
Asyrup ofelixir may contain the active compounds sucrose
US 6,514,942 B1
53
as a sweetening agent methyl and propylparaben as
preservatives, a dye and flavoring, such as cherry or orange
flavor. Of course, any material used in preparing any dosage
unit form should be pharmaceutically pure and substantially
non-toxic in the amounts employed. In addition, the active
compounds may be incorporated into sustained-release
preparation and formulations.
The peptides may be used in their immunizing capacity by
administering an amounteffective to generate an immune
response in an animal. In this sense, such an “amount
effective to generate an immune response” means an amount
of composition that contains a peptide or peptide mixture
sufficient to significantly produce an antigenic response in
said animal.
EXAMPLE5
Methods for Protein Size Determination and Gel
Chromatography
The amino acid sequences disclosed herein, and particu-
larly the tripeptide motifs and multimers thereof, find par-
ticular use in the determination of molecular weights of
small polypeptides. These peptides represent a significant
improvement over commercially-available protein standards
in this area owing to their small size and, since their amino
acid sequence is known, their precise molecular weight is
readily determined.
1. SDS-PAGEAnalysis of Proteins
Commercially-available protein standards for SDS-PAGE
or gel filtration chromatography typically have a range of
3,000 to 200,000 Da (Gibco BRL, Bethesda, Md.), and as
such,are not useful in the characterization of proteins having
molecular weights of about 300 to about 3,000 Da. By
employing peptides of the present invention (e.g., SEQ ID
NOS:1-15) and multimers thereof, a range of suitable low-
molecular weight standards may be readily prepared. Such
a molecular weight ladder mixture may be employed either
in SDS-PAGEorgel filtration protocols which are well-
knownto those of skill in the art (see e.g., Wood, 1981).
2. Paper and Thin-layer Chromatography
In a similar fashion, the polypeptides, and more particu-
larly the tripeptide motifs, of the present invention are
readily employed as standards in the identification of small
molecular-weight polypeptides using chromatographic sepa-
ration. In preferred embodiments, paper chromatographyis
utilized and proteins are subsequently visualized after reac-
tion with ninhydrin. More preferred is the use of thin-layer
chromatography in either one or two dimensions.
3. Gel Filtration Chromatography
The polypeptides of the present invention provide excel-
lent standards for the calibration of chromatographic col-
umns used in the separation of low molecular-weight
polypeptides. In particular, the tripeptide motifs, and mul-
timers thereof, find important use in the standardization of
low-molecular weight-range columns (Rawn, 1983). These
chromatography columns may includea filtration medium
having the capacity to fractionate any protein of interest and
the polypeptides of the present invention. Chromatographic
media such as G-50 or G-25 Sephadex®resins (approximate
fractionation range of 1,500-—30,000 and 100-5,000 Da,
respectively) may be used for generalized separation, or in
cases where the approximate molecular weightof the protein
of interest is known, a medium having a narrowerfraction-
ation range (e.g., G-10 Sephadex® [0-700 Da separation
range] or G-15 Sephadex® [0-1,500 Da separation range])
may be employed. A regression line of the elution position
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versus the log of the molecular weight is established using
the peptides of the present invention, and the molecular
weight of the protein of interest is then determined from this
graph. Detailed protocols for preparation, calibration, and
execution of these columns is well-knownto those of skill
in the art (see e.g., Wood, 1981).
All of the compositions and methods disclosed and
claimed herein can be made and executed without undue
experimentation in light of the present disclosure. While the
compositions and methods of this invention have been
described in terms of preferred embodiments, it will be
apparent to those of skill in the art that variations may be
applied to the composition, methods andin the steps or in the
sequence of steps of the method described herein without
departing from the concept, spirit and scope of the invention.
More specifically, it will be apparent that certain agents
which are both chemically and physiologically related may
be substituted for the agents described herein while the same
or similar results would be achieved. All such similar
substitutes and modifications apparent to those skilled in the
art are deemed to be within the spirit, scope and concept of
the invention as defined by the appended claims.
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SEQUENCE LISTING
(1) GENERAL INFORMATION:
(iii) NUMBER OF SEQUENCES: 68
(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Glu Leu Val Lys Glu Val Ser Lys Val
1 5
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Glu Leu Val Ser Glu Val Ser Lys Val
1 5
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Lys Leu Val Ser Glu Phe Ser Arg Val
1 5
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Gly Leu Val Ser Glu Phe Ser Arg Val
1 5
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
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(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
Glu Leu Val Ser Glu Phe Ser Lys Val
1 5
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
Glu Leu Val Ser Glu Phe Ser Arg Val
1 5
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
Glu Leu Val Ser Glu Phe Ser Arg Met
1 5
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
Val Leu Val Lys Ser Pro Asn His Val
1 5
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Gln Leu Met Pro Tyr Gly Cys Leu Leu
1 5
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
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(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Cys Leu Thr Ser Thr Val Gln Leu Val
1 5
(2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
Lys Ile Phe Gly Ser Leu Ala Phe Leu
1 5
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
Pro Leu Gln Pro Glu Gln Leu Gln Val
1 5
(2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
Thr Leu Glu Glu Ile Thr Gly Tyr Leu
1 5
(2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
Gln Leu Gln Val Phe Glu Thr Leu Glu
1 5
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
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(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
Gly Leu Gly Met Glu His Leu Arg Glu Val
1 5 10
(2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
Asp Leu Gly Met Gly Ala Ala Lys Gly Leu
1 5 10
(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
His Leu Tyr Gln Gly Cys Gln Val Val
5
(2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
Arg Leu Leu Tyr Gln Gly Cys Gln Val Val
1 5 10
(2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
Gly Leu Tyr Gln Gly Cys Gln Val Val
1 5
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
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Asp
(2)
Gln
1
(2)
Asp
(2)
Tyr
(2)
ser
1
(2)
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
Ile Gln Glu Val Gln Gly Tyr Val
5
INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
Leu Arg Ser Leu Thr Glu Ile Leu
5
INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
Ile Phe His Lys Asn Asn Gln Leu
5
INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
Ile Ser Ala Trp Pro Asp Ser Leu
5
INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
Leu Arg Glu Leu Gly Ser Gly Leu
5
INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
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(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
Leu Thr Ser Ile Ile Ser Ala Val
5
INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
Arg Leu Leu Gln Glu Thr Glu Leu Val
5
INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
Ile Pro Val Ala Ile Lys Val Leu
5
INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
Ile Ala Lys Gly Met Ser Tyr Leu
5
INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
Leu Ser Pro Gly Lys Asn Gly Val
5
INFORMATION FOR SEQ ID NO:30:
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(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
His Leu Asp Met Leu Arg His Leu Tyr Gln
1 5 10
(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
Thr His Leu Asp Met Leu Arg His Leu Tyr Gln Gly Cys Gln
1 5 10
(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
Asn Gln Glu Val Thr Ala Trp Asp Gly Thr Gln Arg
1 5 10
(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
Leu Gln Val Phe Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu
1 5 10
(2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
Leu Gln Pro Glu Gln Leu Gln Val Phe Glu Thr Leu Glu Glu Ile Thr
1 5 10 15
Gly Tyr Leu Tyr
20
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(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
Gln Leu Gln Val Phe Glu Thr Leu Glu Glu Ile
1 5 10
(2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
Leu Gln Pro Glu Gln Leu Gln Val Phe Glu Thr Leu Glu
1 5 10
(2) INFORMATION FOR SEQ ID NO:37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:
Glu Leu Val Ser Glu Phe Ser Arg Met Ala Arg
1 5 10
(2) INFORMATION FOR SEQ ID NO:38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:
Arg Phe Arg Glu Leu Val Ser Glu Phe Ser Arg Met Ala Arg
1 5 10
(2) INFORMATION FOR SEQ ID NO:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:
Arg Phe Arg Glu Leu Ile Ile Glu Phe Ser Arg Met Ala Arg
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(2 INFORMATION FOR SEQ ID NO:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:
Leu Val Ser Glu Phe Ser Arg Met Ala Arg Asp Pro Gln
1 5 10
(2 INFORMATION FOR SEQ ID NO:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
Arg Phe Arg Glu Leu Val Ser Glu Phe Ser
1 5 10
(2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
Glu Cys Arg Pro Arg Phe Arg Glu Leu
1 5
(2 INFORMATION FOR SEQ ID NO:43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:
Arg Phe Arg Glu Leu Val Ser
1 5
(2) INFORMATION FOR SEQ ID NO:44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:
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Asp Leu Gly Met Gly Ala Ala Lys Gly Leu
1 5 10
(2) INFORMATION FOR SEQ ID NO:45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:
Phe Asp Gly Asp Leu Gly Met Gly Ala Ala Lys Gly Leu
1 5 10
(2) INFORMATION FOR SEQ ID NO: 46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:
Arg Ile Ala Trp Ala Arg Thr Glu Leu
1 5
(2) INFORMATION FOR SEQ ID NO:47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:
Asn Leu Gly Pro Trp Ile Gln Gln Val
1 5
(2) INFORMATION FOR SEQ ID NO:48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:
Glu Ile Trp Thr His Ser Thr Lys Val
1 5
(2) INFORMATION FOR SEQ ID NO:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:
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Ser Leu Ala Leu Met Leu Leu Trp Leu
1 5
(2 INFORMATION FOR SEQ ID NO:50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:
Leu Leu Ser Leu Ala Leu Met Leu Leu
1 5
(2) INFORMATION FOR SEQ ID NO:51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (4, 6, 9, 12, 18, 19, 20, 21, 24, 27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “Y =C or T; N=A, G, C, or T}; R=A or G; W=
A or T; S$ =C or G"”
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:
GAAYTNGTNA ARGAAGTNWS NAARGTN 27
(2) INFORMATION FOR SEQ ID NO:52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (4, 6, 9, 10, 11, 12, 18, 19, 20, 21, 24,
27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “Y =C or T; N=A, G, C, or T?}; W=AorT; S =
C or G; R=A or G"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:
GAAYTNGTNW SNGAAGTNWS NAARGTN 27
(2) INFORMATION FOR SEQ ID NO:53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of(3, 4, 6, 9, 10, 11, 12, 18, 19, 20, 21,
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22, 24, 27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “R= A or G; Y=C or T; N=A, G, C, or T; W=
Aor T; S =C or G; M=A or Cc”
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
AARYTNGTNW SNGAATTYWS NMGNGTN 27
(2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (3, 4, 6, 9, 10, 11, 12, 18, 19, 20, 21,
22, 24, 27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “"N =A, G, C, or T; Y=C or T}; W=AorT; S =
C or G; M=A or Cc”
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:
GGNYTNGTNW SNGAATTYWS NMGNGTN 27
(2) INFORMATION FOR SEQ ID NO:55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (4, 6, 9, 10, 11, 12, 18, 19, 20, 21, 24,
27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “Y =C or T; N=A, G, C, or T?}; W=AorT; S =
C or G; R=A or G"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:
GAAYTNGTNW SNGAATTYWS NAARGTN 27
(2) INFORMATION FOR SEQ ID NO:56:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (4, 6, 9, 10, 11, 12, 18, 19, 20, 21, 22,
24, 27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “Y =C or T; N=A, G, C, or T?}; W=AorT; S =
C or G; M=A or Cc”
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:
GAAYTNGTNW SNGAATTYWS NMGNGTN 27
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(2) INFORMATION FOR SEQ ID NO:57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (4, 6, 9, 10, 11, 12, 18, 19, 20, 21, 22,
24)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “Y =C or T; N=A, G, C, or T?}; W=AorT; S =
C or G; M=A or Cc”
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:
GAAYTNGTNW SNGAATTYWS NMGNATG 27
(2) INFORMATION FOR SEQ ID NO:58:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (3, 4, 6, 9, 12, 13, 14, 15, 18, 21, 24,
27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “N =A, G, C, or T; Y=C or T}; R=A or G; W=
A or T; S$ =C or G"”
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:
GTNYTNGTNA ARWSNCCNAA YCAYGTN 27
(2) INFORMATION FOR SEQ ID NO:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (3, 4, 6, 12, 15, 18, 21, 22, 24, 25, 27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “R=A or G; Y=CorT; N=A, G, C, or T; R=
A or G;"”
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:
CARYTNATGC CNTAYGARTG YYTNYTN 27
(2) INFORMATION FOR SEQ ID NO:60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
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(A) NAME/KEY: modified_base
(B) LOCATION: one-of(3, 4, 6, 9, 10, 11, 12, 15, 18, 21, 22,
24, 27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “Y =C or T; N=A, G, C, or T?}; W=AorT; S =
C or G; R=A or G"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:
TGYYTNACNW SNACNGTNCA RYTNGTN 27
(2) INFORMATION FOR SEQ ID NO:61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (3, 6, 9, 12, 13, 14, 15, 16, 18, 21, 24,
25, 27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “R= A or G; H=A, C, or T} Y=C or T; N=A,
G, C, or T; W= A or T; S = C or G"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:
AARATHTTYG GNWSNYTNGC NTTYYTN 27
(2) INFORMATION FOR SEQ ID NO:62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (3, 4, 6, 9, 12, 15, 18, 19, 21, 24, 27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “N =A, G, C, or T; Y =C or T; R=A or G"”
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:
CCNYTNCARC CNGARCARYT NCARGTN 27
(2) INFORMATION FOR SEQ ID NO:63:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (3, 4, 6, 9, 12, 15, 18, 21, 24, 25, 27)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “N =A, G, C, or T; Y=C or T}; R=A oor G; H =
A, C, or T;”
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:
ACNYTNGARG ARATHACNGG NTAYYTN 27
(2) INFORMATION FOR SEQ ID NO:64:
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(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: one-of (3, 4, 6, 9, 12, 15, 18, 21, 22, 24)
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “R= A or G; Y =C or T; N=A, G, C, or T”
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:
CARYTNCARG TNTTYGARAC NYTN 24
(2) INFORMATION FOR SEQ ID NO:65:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:
Arg Phe Arg Glu Leu Val Ser Glu Phe Ser Arg Met Ala Arg
1 5 10
(2) INFORMATION FOR SEQ ID NO:66:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:
Arg Phe Arg Glu Leu Ile Ile Glu Phe Ser Arg Met Ala Arg
1 5 10
(2) INFORMATION FOR SEQ ID NO:67:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:
Ser Leu Ala Asp Pro Ala His Gly Val
1 5
(2) INFORMATION FOR SEQ ID NO:68:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
US 6,514,942 B1
87 88
-continued
 
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:
Gly Leu Thr Ser Ala Pro Asp Thr Arg Val
1 5 10
Whatis claimedis:
1. A purified peptide comprising the amino acid sequence
of SEQ ID NO:11, wherein said peptide induces Her-2
peptide reactive cytotoxic T-lymphocytes.
2. The purified peptide of claim 1 consisting of the amino
acid sequence of SEQ ID NO:11.
3. A pharmaceutical composition comprising the peptide
of SEQ ID NO:11 in a pharmaceutical acceptable excipient,
wherein said peptide induces Her-2 peptide reactive cyto-
toxic T-lymphocytes.
4. The peptide of claim 1, further defined as a peptide of
between 9 and 20 aminoacid residues in length.
5. The peptide of claim 4, further defmed as a peptide of
between 9 and 15 aminoacid residues in length.
6. The peptide of claim 5, further defined as a peptide of
9 or 10 aminoacid residues in length.
7. A composition comprising a peptide including the
amino acid sequence of SEQ ID NO:11, wherein said
peptide induces Her-2 peptide reactive cytotoxic
T-lymphocytes.
8. The composition of claim 7, wherein the peptide is
between 9 and 20 aminoacid residues in length.
9. The composition of claim 8, wherein the peptide is
between 9 and 15 aminoacid residues in length.
10. The composition of claim 9, wherein the peptide is 9
or 10 amino acid residues in length.
11. The composition of claim 7, further comprising a
peptide including the amino acid sequence of SEQ ID NO:7.
12. The composition of claim 7, further comprising a
peptide including the amino acid sequence of SEQ ID NO:8.
13. The composition of claim 7, further comprising a
peptide including the amino acid sequence of SEQ ID
NO:10.
14. The composition of claim 11, further comprising a
peptide including the amino acid sequence of SEQ ID NO:8.
15. The composition of claim 14, further comprising a
peptide including the amino acid sequence of SEQ ID
NO:10.
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16. The composition of claim 11, further comprising a
peptide including the amino acid sequence of SEQ ID
NO:10.
17. The composition of claim 12, further comprising a
peptide including the amino acid sequence of SEQ ID
NO:10.
18. The pharmaceutical composition of claim 3, further
comprising a peptide including the amino acid sequence of
SEQ ID NO:1.
19. The pharmaceutical composition of claim 3, further
comprising a peptide including the amino acid sequence of
SEQ ID NO:2.
20. The pharmaceutical composition of claim 3, further
comprising a peptide including the amino acid sequence of
SEQ ID NO:3.
21. The pharmaceutical composition of claim 3, further
comprising a peptide including the amino acid sequence of
SEQ ID NO-4.
22. The pharmaceutical composition of claim 3, further
comprising a peptide including the amino acid sequence of
SEQ ID NO:5.
23. The pharmaceutical composition of claim 3, further
comprising a peptide including the amino acid sequence of
SEQ ID NO:6.
24. The pharmaceutical composition of claim 3, further
comprising a peptide including the amino acid sequence of
SEQ ID NO:9.
25. The pharmaceutical composition of claim 3, further
comprising a peptide including the amino acid sequence of
SEQ ID NO:18.
26. The pharmaceutical composition of claim 3, further
comprising a peptide including the amino acid sequence of
SEQ ID NO:19.
